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SUMMARY 
Many children have asthma-like wheezing symptoms during their first years of life, yet only a 
minority develop asthma. Attempts to identify wheezing children at increased risk of asthma 
have been conducted, but the value for the clinician has been limited. The risk of developing 
asthma is influenced already in utero if the foetus is exposed to maternal tobacco smoke, but 
prior studies have not been able to differentiate pre- and postnatal smoke exposure effects. 
Conversely, the role of foetal or early postnatal smoke exposure for the risk of allergic 
sensitization in childhood is still under debate. It has been suggested that allergies may play a 
role in the pathogenesis of recurrent abdominal pain due to a mutual immunologic origin. 
Previous studies investigating potential associations between allergy-like symptoms, IgE-
reactivity and abdominal pain have shown contradictory results. 
The aim of the epidemiological studies in this thesis were to contribute to the knowledge on 
the role of pre- and early postnatal tobacco smoke exposure for the development of asthma 
and aeroallergen sensitization in children. We also explored which clinical risk factors and 
comorbidities to wheezing in infancy that were associated with having asthma at school age. 
Moreover, associations between allergy-related symptoms and IgE-reactivity during 
childhood and recurrent abdominal pain at age 12 years were investigated.  
The results regarding risks of tobacco smoke exposure were based on data from eight 
European birth cohorts consisting of a total of 32,774 children. The studies on wheeze and 
school age asthma as well as allergy-related symptoms and abdominal pain were based on 
data from the population-based Swedish birth cohort BAMSE consisting of 4,089 children. 
In study I we showed that among the children that wheezed at least once during their first two 
years of life, the risk of school age asthma was almost fourfold. Allergic heredity, increased 
severity of wheeze, infant eczema and recurrent abdominal pain were independent risk factors 
for having asthma at age eight years. In study II, maternal tobacco smoking during pregnancy 
was associated with an increased risk of wheeze or asthma in preschool children even among 
the children that had not been exposed late in pregnancy or after birth. We observed no 
convincing associations between early second hand tobacco smoke exposure and sensitization 
to pets, house dust mite, pollen or all aeroallergens combined in preschool or school age in 
study III. In study IV all allergy-related diseases at the age of 12 years were associated with 
recurrent abdominal pain at the same age. Moreover, food sensitization and food allergy at 
age four or eight years were also associated with recurrent abdominal pain at age 12 years.  
The results of this thesis consolidate previous knowledge regarding early factors associated 
with childhood asthma development. The significant association between allergy-related 
diseases and recurrent abdominal pain supports the hypothesis of a mutual immunologic 
pathway. The knowledge that maternal smoking during pregnancy is associated with wheeze 
and asthma in preschool children, even if they were not exposed late in pregnancy or after 
birth, should be used to motivate women not to start smoking or to quit before conceiving to 
prevent asthma in their children.  
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1 BACKGROUND 
1.1 ALLERGIC DISEASES 
1.1.1 Nomenclature 
Allergic diseases such as asthma, eczema and allergic rhinitis are chronic inflammatory 
disorders caused by immune responses against common environmental substances, usually 
proteins
1
. Proteins that can cause allergy in susceptible individuals are called allergens. 
Allergy is defined as “a hypersensitivity reaction initiated by immunological mechanisms” 
whereas non-allergic hypersensitivity is used in the absence of proven immunological 
mechanisms
2-4
. The immunological mechanisms can be mediated by B-cells or T-cells. In 
most cases, the allergic reaction belongs to the IgE antibody isotype and the patient is said to 
have IgE mediated allergy
2
. The process when an individual acquires increased sensitivity to 
an allergen is called sensitization
2
.  
Atopy is a term for the personal and/or familial tendency, usually in childhood or 
adolescence, to become sensitized and produce IgE antibodies to “innocuous” proteins4. As a 
consequence, typical allergic symptoms can develop although the term atopy does not include 
clinical symptoms
4
. 
 
1.1.2 The sensitization process 
The sensitization process starts when an allergen enters through the skin or through the 
mucosal membranes in the airways or gut and is taken up by an antigen presenting cell (APC) 
and transported to a regional lymph node where Th0 (naïve) CD4+ cells are stimulated to 
develop into Th2 cells (Th=T-helper cell)
5
. Cytokines (cell signalling proteins) such as IL-4 
and IL-13 produced by the Th2 cells stimulate B-cells to form allergen-specific IgE-
antibodies. These IgE-antibodies adhere to cell surfaces of mast cells and basophils which 
migrate to the mucous membranes and around blood vessels awaiting new contact with the 
allergen. On the other hand, if Th1, Th17 or T-regulatory cells are formed from naïve Th0 
cells instead of Th2 cells when encountering the APC, the sensitization process is suppressed 
or not initiated. This description of the sensitization process is a simplified version. In reality 
it is much more complex, depending on a balance between Th1 and Th2 cell numbers and 
activity, specific local cytokine environment and type of encountered allergen
5
.  
When the sensitized individual is reexposed to the specific allergen, this is recognized by the 
previously formed IgE-antibodies on the mast cell or basophil surfaces. Cross-linking of two 
IgE-antibodies on the cell surface activates signalling pathways into the cell inducing 
degranulation with release of preformed inflammatory mediators such as histamine, 
leukotriens, heparine, proteases and tryptase
5
 which give rise to the allergic inflammation. 
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1.1.3 Allergic inflammation 
The allergic inflammation that arises upon mast cell or basophil activation causes different 
symptoms depending on affected organ but the underlying inflammation is similar, with 
increased capillary permeability and vasodilatation resulting in swelling/secretion and 
redness, and nerve stimulation causing itch, sneeze or constriction of smooth muscle
5
. For 
example, typical symptoms localized to the skin are itching rashes in eczema or red, raised 
itchy wheals in allergic urticaria. A runny, blocked, itchy nose with frequent sneezing is 
typical of allergic rhinitis. Usually symptoms develop within minutes after exposure.  
Selected cytokines (such as IL-4 and IL-5) and chemokines produced by mast cells and Th2 
cells also promote growth and development of inflammatory cells that migrate to the site. 
These cells, for example eosinophils, further enhance inflammation which can result in 
prolonged or biphasic allergic reactions
6
. These delayed reactions as well as chronic allergen 
exposure may cause tissue damage such as airway remodelling in asthmatics. 
 
1.1.4 Disease prevalence  
Allergic diseases such as asthma, eczema and allergic rhinitis have become more frequent 
during the latter half of the 20
th
 century, particularly among children
7
. Recent worldwide 
population estimates show wide geographical variations and mixed time trend patterns
8
. 
Overall, allergic diseases are still on the rise, especially in countries with a historically lower 
prevalence of allergy
8
, although asthma seems to have reached a plateau or even decreased 
slightly in the last decades in countries with an already high prevalence
8
. Today, allergic 
diseases affect up to every third child or adolescent in Europe
9, 10
 and asthma is the most 
common chronic childhood disease in nearly all industrialized countries, giving rise to 
substantial morbidity
7, 11
.  
According to the International Study of Asthma and Allergies in Childhood (ISAAC), the 
prevalence of asthma symptoms in Sweden is around 10% in children aged six to seven years 
and 13 to 14 years, which is comparable with most of Western Europe
8
. The corresponding 
prevalence for allergic rhinitis is around 7% and 10%, and for eczema 22% and 13% at the 
two respective ages
8
. Apart from the negative impact on the quality of life of affected 
children and families, the high prevalence makes allergic diseases a serious public health 
issue. 
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1.1.5 Disease aetiology and risk factors 
The aetiology of allergic diseases is multifactorial and complex. A genetic disposition as well 
as appropriate timing of environmental exposures to certain stimuli is required for atopy and 
allergic diseases to develop
1, 12, 13
. In addition, sex and allergic heredity may modify effects of 
exposures
14-16
, and environmental exposures may influence the expression of important 
genes
17
.  
Changes in environment and lifestyle in the last decades are considered dominating factors 
for the increment in prevalence of atopy and allergic disease since the pace of this increase 
has been much faster than the genetic constitution can possibly shift
1
. Moreover, variations in 
allergy prevalence exist even between genetically similar groups
7, 8, 18
. A crucial window for 
harmful impact of environmental and lifestyle factors appear to exist in prenatal and early 
postnatal life, as immune and lung development occur largely during these periods
19, 20
.  
In 1989, Strachan suggested that reduced exposure to infections in early childhood could 
enhance development of allergic diseases
21
. This hypothesis that has later been known as “the 
hygiene hypothesis”, was based on observations from a cohort of 17,414 British children, 
where the prevalence of hay fever and infantile eczema at age 11 and 23 years were inversely 
related to the number of older siblings
21
. An alternative interpretation of this hypothesis is 
that altered bacterial colonization in infancy could be responsible for the increase in allergic 
diseases due to changes in exposure to various microbial agents
1
. This is supported by 
observational studies confirming an inverse relation between other indirect markers of 
microbial exposure, such as living close to farm animals
22-24
 and the development of atopy 
and allergic diseases. Thus, it is currently believed that changes related to improved hygiene 
and healthcare in the developed world have altered the pattern of exposure to infectious 
and/or microbial agents in early life, predisposing the immune system towards an atopic 
response
1, 18, 21, 25
. However, which microbiota that are involved and the mechanisms are still 
unclear. 
Furthermore, the steady increase of asthma prevalence shares the trajectory of increasing air 
pollution and population trends towards urban centres
26
. Current research suggests that air 
pollution from different sources such as traffic, heating and environmental tobacco smoke
27-29
 
likely play an important role in the pathogenesis of asthma
30
.  
Several birth cohorts have demonstrated a relationship between early sensitization to 
aeroallergens and subsequent asthma persisting into school age and beyond
26, 31-34
. Infants 
and children spend most of their time at home or at day care, making the indoor environment 
an important source of early life allergens. Aeroallergens accounting for the vast proportion 
of sensitization in this context are house dust mite and furred pets (cats)
35-37
. Indoor 
dampness/mould is also associated with increased asthma prevalence
38
. Moreover, viral 
respiratory infections in infancy are associated with asthma development
39, 40
 although it is 
still unclear whether the virus itself causes immunological changes that lead to asthma or if 
affected infants already destined for asthma develop more severe symptoms
26
. Many other 
factors than the ones reported in this thesis have been associated with asthma or atopy, for 
example dietary factors and obesity
41, 42
. 
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1.1.6 Disease progression during childhood 
Symptoms of allergic disease often follow a typical sequence of progression during 
childhood, starting with eczema in the first months of life
43
. Food allergies, especially to 
cow’s milk and egg are also common early in life and wheeze often debuts in the second half 
of the first year
44, 45
. In school-aged children allergic rhinitis and asthma become more 
prevalent, combined with increasing aeroallergen sensitization
43, 46
. However, although 
different allergic symptoms are more common at different ages as described above, the same 
symptom sequence is not always present at the individual level and comorbidity of symptoms 
are more of a rule than an exception
47
. Furthermore, allergic disease development is a 
dynamic process, with both new cases and remission being common throughout childhood
47
.  
 
1.1.7 Comorbid symptoms and consequences of disease 
Besides anaphylaxis that is potentially life-threatening with an allergic reaction involving 
several organs, data indicate that local exposure to an allergen can mediate systemic disease 
manifestations expressed also beyond organs commonly viewed as part of an allergic disease 
due to common immunological mechanisms
5, 48, 49
. Already in the seventies, Peckham et al. 
observed that recurrent headaches, migraine and recurrent abdominal pain were more 
frequent among eleven-year-olds with “wheezy bronchitis” compared to children without 
symptoms
50
. Later studies have shown similar associations
48, 51-55
. For example, Tollefsen et 
al. found that allergic wheeze and involvement of increasing combinations of wheeze and 
other allergic expressions (allergic rhinitis and eczema), increased the reporting of other 
health problems such as headache, abdominal pain or muscle pain among Norwegian 
adolescents
48
. Moreover, several studies have reported that allergic conditions are found in 
excess among patients with functional gastrointestinal disorders and irritable bowel syndrome 
(IBS), suggesting that this might (at least partly) be due to coexisting low-grade 
inflammation
53, 54, 56-62
. With regard to associations between food hypersensitivity and 
abdominal pain, the results have been conflicting although patients with abdominal pain often 
report that specific foods induce or worsen gastrointestinal symptoms
62-67
. 
The concept of a common mucosal immune system suggests that, since activated 
lymphocytes can migrate from one mucosal site to another for example between the lung and 
gut, there exists a potential to cause an inflammatory response at both sites
6, 49, 68, 69
. This 
concept is supported by the fact that airway-like cell infiltration of the duodenal and intestinal 
mucosa in patients with asthma and allergic rhinitis has been described
6, 69
. Several studies 
have observed disturbances in the immune system in the intestinal mucosa and peripheral 
blood of irritable bowel syndrome (IBS) patients such as an increased number of eosinophils 
and mast cells
70-72
. These cells are central in the pathogenesis of allergic disease, but mast 
cells also play a role for chronic pain perception, particularly at the visceral level
73
. Barbara et 
al. have shown that mast cell degranulation in close proximity to nerves innervating the 
colonic mucosa is correlated with abdominal pain perception in patients with IBS
74
. Thus, 
allergies are suggested to play a role in the pathogenesis of chronic abdominal pain due to a 
mutual immunologic origin, at least in a subgroup of patients
62, 70, 75
. Several studies have 
explored the relationship between asthma
50, 55, 58, 60, 76-78
, allergic rhinitis
55, 62, 79
, food 
hypersensitivity
61, 65, 66, 77, 80, 81
 and eczema
55, 62, 79
 in relation to abdominal pain, with 
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contradictory results. Most studies have been based on small, selected study samples and the 
study designs have not often been prospective and few have included children
50, 66, 79
. More 
knowledge about the relationship between allergy-related symptoms, IgE-reactivity and 
recurrent abdominal pain in children is of importance since therapeutic options may differ 
between atopic and non-atopic children with recurrent abdominal pain.  
Although not studied in this thesis, there are also other consequences of allergic disease in 
children such as reduced health-related quality of life
82
 and increased susceptibility to various 
infections
83, 84
. 
 
1.2 ASTHMA  
1.2.1 Definition and phenotypes  
According to the latest version of the international guidelines for asthma treatment, GINA 
2015, asthma is “a heterogeneous disease, usually characterized by chronic airway 
inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness 
of breath, chest tightness and cough that vary over time and in intensity, together with 
variable expiratory airflow limitation”85. Chronic and/or recurrent airway inflammation, 
mucous hypersecretion, and airway smooth muscle mediated bronchoconstriction cooperate 
to create the airflow limitation, symptoms and signs of asthma
12, 26
. 
Many different phenotypes of asthma have been identified, but more research is needed to 
prove their clinical usefulness. The dominating phenotype in school children and adolescents 
is allergic asthma
13, 26
. Airway inflammation with eosinophilia and/or neutrophilia is often 
present, with good therapeutic response to inhalant steroid medication. This phenotype is 
often associated with other allergic manifestations and the vast majority of teenagers with 
asthma are sensitized to aeroallergens. A less common asthma phenotype in childhood, non-
allergic asthma, comprises variable expiratory airflow limitation and typical respiratory 
symptoms without inflammatory markers.  
 
1.2.2 Diagnostic criteria, clinical features and trigger factors  
The diagnosis of asthma in infants and preschoolers is based on patient’s history and typical 
symptoms. The main symptoms are wheezing or whistling breathing sounds, forced or heavy 
breathing, nocturnal cough, cough during activity, prolonged cough after common colds and 
reduced energy/physical performance. The most common trigger factors for exacerbations 
and worsening of asthma symptoms are viral respiratory tract infections and exercise but also 
allergens, cold air, tobacco smoke and strong scents. In some cases, simple exercise tests are 
performed and in less certain cases, treatment with inhalant steroids can be tested to see if 
improvement occurs. Allergy testing is most often conducted. However, it is important to 
keep in mind that all that wheezes is not asthma, and differential diagnoses must be 
considered, especially in wheezy infants below age six months. In children from age five to 
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six years, objective measurements of lung function such as peak expiratory flow curves, 
spirometry and fractional exhaled Nitrous Oxide can be used to verify the diagnosis and for 
follow-up of symptoms and treatment effects.  
 
1.2.3 Prediction of disease  
In a large proportion of school age children with asthma, asthma-like symptoms were present 
already during the first years of life. On the other hand, only approximately 30% of preschool 
wheezing children have asthma at school age
31
. It is currently believed that infants and 
preschoolers with chronic wheezing symptoms that are triggered by multiple stimuli are at 
higher risk of developing asthma due to underlying structural or functional airway changes 
aggravated by airway inflammation, compared to children with mild episodic wheeze
86
.  
Since data suggest that early asthma symptoms are associated with deterioration of lung 
function and persistence of symptoms into adulthood, identifying these children early is of 
importance for developing tailored treatment strategies and improve follow-ups to decrease 
disease burden
31, 87, 88
. Detecting children at low risk of asthma is also important in order to 
reduce unnecessary treatment with potential side-effects. One obstacle is that no objective 
measurements for asthma can be used in this young age group
31
. 
Several attempts have been done over the years to develop predictive risk indices that can be 
used in clinical practice for identifying children with early respiratory symptoms at higher 
risk of developing asthma, such as the asthma predictive index
31
 the PIAMA risk score
87
 and 
the recent clinical asthma prediction score
88
. Factors suggested useful for identification of 
early-onset asthma in wheezers include a family history of asthma or atopy
31, 87, 88
, eczema
87
, 
allergic rhinitis
31
, low socio-economy
87
, respiratory tract infections
87, 89
 and sex
87, 90
. Some 
prediction rules include results from IgE or eosinophil screening tests
31, 88, 89
, and it may be 
argued that this is not simple to incorporate in general clinical practice
91
. Subdivision of 
wheeze into categories with regard to timing and persistence of symptoms such as early-
onset, persistent, late, transient and intermediate wheezers up to early school age have been 
done in several studies
32, 86, 89
. These categories are relevant in epidemiological studies but 
less useful for clinicians since asthma prediction becomes important as soon as symptoms 
appear. Caregivers seeking health care for their wheezing children want to know the 
prognosis at the time being, not later on.  
In conclusion, the tools for identifying wheezers that will develop asthma are not yet 
applicable in clinical practice
92
. Thus, the challenges remain for clinicians to decide on which 
treatment that can be effective and which information to give the parents. 
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1.3 SECOND HAND TOBACCO SMOKE  
1.3.1 Second hand smoke exposure prevalence in children 
Exposure to second hand smoke (SHS), also known as passive smoking or environmental 
tobacco smoke, is the involuntary inhalation of other people’s cigarette smoke93. Globally, 
around 40% of children are exposed to SHS
94
 and the main source of smoke exposure during 
childhood is from tobacco smoking by the caregivers in the home environment
93, 95
. The 
greatest contributor of SHS exposure in children is a smoking mother
96
. Newborns and 
infants spend most of their time in the home environment, thereafter the prevalence of SHS 
exposure declines with age due to more time being spent outside the home
97
. The smoke-free 
legislations banning smoking in public places that have been introduced in many countries in 
the last decade do not include private households
93
. According to information from the World 
Health Organization, children accounted for 28% of the deaths attributable to SHS in 2004
98
.  
 
Results from the Children’s Environmental Health Survey, a comprehensive survey including 
36,000 Swedish children
99
, showed that 5% of women reported that they smoked at some 
point during pregnancy in 2011. This is a decrease compared to results from the same study 
conducted in 2003, when 9.5% of the women reported smoking during pregnancy. Moreover, 
the proportion of children with at least one parent being a daily smoker almost halved 
between 2003 and 2011. In 2011, about 11% of 12-year-olds, 9.6% of four-year-olds, and 
7.5% of eight-month-old Swedish children had at least one parent who smoked. However, 
there was a clear difference between children’s environments with regard to parental 
education. No reduction of smoking during pregnancy was seen in women with less than high 
school education and the decrement in tobacco smoking was seen in the group of parents that 
had completed high school, but among less educated parents the prevalence remained 
unchanged at almost 40%.  
 
1.3.2 Composition of second hand tobacco smoke 
Cigarette smoke is an aerosol that contains extremely fine droplets suspended in a complex 
gaseous system. The two kinds of SHS that are produced while smoking are side stream and 
mainstream smoke. Side stream smoke is released from the lit end of the cigarette and 
mainstream smoke is the smoke exhaled by the smoker. When burned, cigarettes emit more 
than 7,000 chemicals including 70 mutagens according to the American Cancer Society
100
. 
Although SHS becomes diluted in ambient air it contains significant levels of nicotine. 
Nicotine has been the focus of most animal model studies and human epidemiological studies 
on the effects of smoking
101
 and despite the large number of chemicals present in tobacco 
smoke it has been suggested that many of the adverse effects on the foetus and neonate are 
due to the nicotine
102
. 
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1.3.3 Foetal and early second hand smoke exposure and childhood 
respiratory morbidity 
Children are especially susceptible to SHS due to their growing and differentiating organs 
and tissues
94, 96, 103
. Infants under two years of age may be particularly susceptible to the 
adverse effects of SHS exposure as they have a high respiration rate
103, 104
 and immature 
lungs
95
. After delivery, infants are exposed to tobacco constituents through the breast during 
lactation besides through respiration, and the nicotine concentration in mother’s milk is two 
to three times higher than in the mother’s plasma102. 
Unborn children are also passive smokers, and the levels of tobacco constituents from 
maternal smoking during pregnancy have been calculated to be at least 30 times higher than 
exposure levels achieved by environmental tobacco smoke alone
105
. Circulating nicotine in 
the mother’s blood reaches the foetus through the placenta together with harmful particulate 
matter, resulting in decreased amounts of oxygen and nutrients to the foetus which impairs 
foetal cell growth and development
96
.  
The foetal lungs have a very high affinity for nicotine due to nicotinic acetylcholine receptors 
present in the foetal lung
102
. There is growing evidence that nicotine may be the key 
constituent of cigarette smoke that alters lung development in the offspring, leading to 
impaired lung function and an increased risk of respiratory illness
102
. According to a recent 
review by Maritz et al, several nicotine induced changes have been demonstrated in the lungs 
of animal models after foetal SHS exposure, for example thickening of airway walls, collagen 
accumulation, airway narrowing, impaired cell proliferation in the bronchial epithelium, 
reduced surface complexity in the lung parenchyma and reduced internal surface area
102
. 
Epidemiological studies indicate that lung function and susceptibility to respiratory diseases 
throughout life can be programmed by environmental factors, such as SHS, operating during 
foetal and early postnatal life
102
. Associations have been reported between smoking during 
pregnancy or infancy and impaired lung function
106
 as well as lower airway obstruction with 
symptoms of wheeze
107-113
 and asthma
108, 114-117
 in children.  
Despite extensive research, the potential independent role of in utero tobacco smoke exposure 
on childhood wheeze and asthma has been unclear due to the challenge of disentangling 
prenatal and postnatal associations since most women continue smoking after delivery
118, 119
. 
Since different biological mechanisms may influence respiratory disease development before 
and after birth
116
, assessing associations between pre- and postnatal SHS exposure and 
childhood wheeze or asthma separately could provide new insights. Moreover, the impact of 
smoke exposure on respiratory disease development may differ early and late in pregnancy 
and in previous epidemiological studies the timing of SHS exposure in pregnancy in relation 
to asthma in the offspring has not been possible to assess. 
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1.3.4 Foetal and early life second hand smoke exposure and aeroallergen 
sensitization development during childhood 
The evidence for a causal relationship between pre- and postnatal SHS exposure and 
asthmatic symptoms and reduced lung function in children is quite strong. In contrast, the 
evidence related to the development of aeroallergen sensitization is much weaker
95
. In theory 
and with support from some studies based on animal models
120-122
, a number of potential 
mechanisms exist by which air pollutants such as SHS may enhance aeroallergen 
sensitization. For example, SHS may act as an independent aggravator of the airway 
epithelium, or aeroallergens may adhere to SHS particulate matter making this an easy 
conduit for allergen-induced airway inflammation. SHS may also have an adjuvant effect on 
local allergens
26, 30
. Furthermore, SHS may influence the maturation of the immune system 
and modulate immune responses
123, 124
. 
In 1998, Strachan and Cook concluded that pre- or early postnatal parental smoking is 
unlikely to increase the risk of allergic sensitization in children after having reviewed existing 
epidemiological studies
125
. Later studies have shown conflicting results
126
 reporting 
increased
29, 110, 127
, reduced
128
 as well as no
111, 129, 130
 associations between early SHS exposure 
and aeroallergen sensitization. However, some of these studies observed significant 
associations only in children with or without allergic heredity, thus the role of heredity as an 
effect modifier is also unclear. A recent review by Feleszko et al based on nineteen 
population-based studies concluded that household SHS increases the sensitivity to allergens 
in children by influencing postnatal immunoregulation
28
.  
In conclusion, both reviews and studies report diverging results regarding the association 
between SHS and aeroallergen sensitization although some evidence exists regarding altered 
immune responses and tobacco smoke induced sensitization in animal models. 
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1.4 AIMS 
The overall aim of this thesis was to assess potential consequences of early life tobacco 
smoke exposure and allergic comorbidity for the development of asthma, IgE-reactivity or 
recurrent abdominal pain during childhood in the general paediatric population.  
The study-specific aims were: 
 To identify clinical risk factors for asthma in eight-year-old children that wheezed 
during infancy. 
 
 To assess associations between exposure to maternal smoking during pregnancy and 
wheeze or asthma in preschool children. 
 
 To investigate associations between exposure to maternal smoking during pregnancy 
or early infancy and aeroallergen sensitization to pets, house dust mite and pollen in 
preschool and school age children. 
 
 To examine if allergy-related diseases or IgE-reactivity during childhood are 
associated with increased risks of recurrent abdominal pain at age 12 years. 
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2 MATERIALS AND METHODS 
2.1 STUDY SUBJECTS 
Study I and IV are based on data from the BAMSE birth cohort. Study II and III are pooled 
analyses containing individual participant data from eight European cohorts including 
BAMSE. 
2.1.1 The BAMSE birth cohort 
BAMSE is a Swedish acronym standing for Barn (Children), Allergi (Allergy), Miljö 
(Environment), Stockholm, Epidemiologi (Epidemiology). This longitudinal, population-
based birth cohort consists of children born in four predefined areas in the central and north-
western parts of Stockholm (Järfälla, Solna, Sundbyberg and parts of Stockholm inner city). 
These areas cover both urban and suburban environments with varying socio-economy and 
living conditions
131
.  
The primary aim of the BAMSE study is to assess risk factors for developing allergy-related 
diseases in childhood
131. The study is ongoing, and the originally recruited “BAMSE-
children” are currently in their early twenties.  
2.1.1.1 Recruitment 
Enrolment took place between February 1994 and November 1996. Information on newborns 
in the areas of interest was retrieved from the community population register. Parents were 
asked about participation at the first scheduled postnatal visit at the child health care centre. 
During time of enrolment, 7,221 children were born in the study areas. Out of these children, 
477 could not be reached and another 1,256 were actively excluded leaving 5,488 eligible 
children for the study. The flow chart in Figure 1 describes the included and excluded 
children at recruitment.
 
Figure 1 Flow chart of included and excluded children at recruitment to BAMSE  
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In 1996, the families who declined participation or were actively excluded were sent a short 
questionnaire on background characteristics to enable evaluation of potential selection into 
the study. The response rates for families declining to participate was 83%, and for the 
actively excluded families 58%. Smoking was more common among these parents, but no 
significant differences were seen with regard to pet ownership or allergy-related disease
131
.  
The final number of included children was 4,089 which was about 75% of all eligible 
newborns. When the infants were two months old (median age), the parents answered postal 
questionnaires regarding parental allergy-related diseases, lifestyle factors, socio-economy 
and residential characteristics.  
2.1.1.2 Follow-ups 
When the children were one, two, four, eight, and 12 years, questionnaires focusing on key 
exposures and allergy-related symptoms in the children were answered by the parents. The 
response rates at the respective ages were 96%, 94%, 91%, 84% and 82%. At the age of 12 
years, apart from the parents, questionnaires were also answered by the children themselves. 
The 12-year questionnaires were sent out at a single time point in springtime 2008 when the 
children were at a mean age of 12.9 years, (eleven to 14 years). 
All children whose parents answered the questionnaires at four and eight years were offered 
clinical examination including blood sampling regarding common food and airborne 
allergens. Serum samples were drawn from 2,614 (64%) and 2,461 children (60%) at the 
respective ages. Figure 2 describes the periods of data collection up to 12 years. 
 
Figure 2 Periods of data collection and response rates up to 12 years in the BAMSE 
birth cohort   
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2.1.2 The ENRIECO collaboration 
The ENRIECO (Environmental health risks in European birth cohorts) project started in 2009 
with the objective to advance knowledge on relationships between environmental 
contaminants and child health
132
. The project received financial support from the European 
Commission for this purpose. European pregnancy and birth cohorts with ethical approval 
from local review boards were allowed to participate.  
2.1.2.1 Overview of the birth cohorts 
Researchers from BAMSE participated in the identification and evaluation of the cohorts 
with data on tobacco smoke and allergy-related symptoms in ENRIECO
133
. The cohorts with 
sufficient data (including BAMSE) were included in the pooled analyses in study II and III. 
An overview of these birth cohorts is provided in Table 1. 
 
Table 1 Overview of the European cohorts: cohort acronym and country, years of recruitment, the 
number of children enrolled in each cohort at baseline and proportions included in study II and III 
Acronym, country Recruitment N, Baseline  N, Study II  N, Study III 
ALSPAC, U.K. 1991-1992 14,057 7,608 (54%) 5,655 (40%) 
AMICS-Menorca, Spain 1997-1998 482 441 (91%) 349 (72%) 
BAMSE, Sweden 1994-1996 4,089 3,673 (90%) 3,041 (74%) 
DARC, Denmark 1998-1999 562 495 (88%) 396 (70%) 
GINIplus, Germany 1995-1998 5,991 3,794 (63%) 1,931 (32%) 
LISAplus, Germany 1997-1999 3,097 1,760 (57%) 1,054 (33%) 
MAS, Germany 1990 1,314
 
894 (68%) 793 (60%) 
PIAMA-NHS, The Netherlands 1996-1997 3,182 2,935 (92%) 1,394 (44%) 
Total   32,774 21,600 (66%) 14,613 (45%) 
 
Three additional cohorts provided data but were excluded before the analysis stage due to 
insufficient exposure or outcome information. These were NINFEA, Co.N.ER (Italy) and 
KOALA (The Netherlands). 
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2.2 STUDY POPULATIONS  
In study I we included 3,251 children from the BAMSE birth cohort who participated at one, 
two, and eight years with available information on symptoms related to wheeze, eczema and 
rhinorrhoea at one and two years and on asthma at age eight years. There were 823 children 
that wheezed before age two years in the study population (infant wheezers). 
In study II we required complete data on maternal smoking from at least one time point 
during pregnancy and from the first year after birth as well as information regarding wheeze 
symptoms or asthma between ages four to six years for cohorts from the ENRIECO 
collaboration. In total, 21,600 children could be divided into four exclusive pre- and postnatal 
smoke exposure groups.  
Study III is based on 14,613 children from the ENRIECO collaboration with available data 
on maternal smoking from any time point during pregnancy and maternal smoke exposure 
assessment in the first year after delivery. We also required data on IgE antibody 
concentrations to at least one specific allergen based on serum or SPT tests from at least one 
of ages three or four years or six, seven or eight years from all cohorts.  
Study IV comprised 2,610 children from the BAMSE birth cohort that participated in the one, 
two, four, eight and 12 year follow-ups without diagnosed coeliac disease or irritable bowel 
disease. Available answers on questions on abdominal pain and coeliac/inflammatory disease 
were required. Subgroup analyses were performed in 2,289 children with available serum IgE 
samples age four and/or eight years. 
 
2.3 DEFINITIONS OF EXPOSURES AND OUTCOMES 
2.3.1 Definitions of background characteristics (I, II, III, IV) 
The study populations were compared to the original cohorts regarding certain characteristics 
in order to assess potential selection bias and generalizability of the results. These 
characteristics are defined in Table 2. Recruitment and collection of background information 
took place during pregnancy or in the first months postpartum in the European cohorts.  
Although data were harmonized before the analyses in study II and III, some variation in the 
definitions was unavoidable due to differences between the wordings in the original 
questionnaires. For example, exclusive and partial breast feeding was rarely reported 
separately and duration was recorded no longer than six months in half of the cohorts. 
Moreover, questions regarding home dampness and mould were particularly heterogeneous. 
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Table 2 Definitions of background characteristics 
Variable Definition   Study 
Socioeconomic 
status 
Socioeconomic status for the household according to dominance, 
dichotomized into blue collar worker (low) and white collar worker (high).  
I, IV 
Maternal age Mother’s age 25 years or less at delivery. I, IV 
Parental 
education 
Divided into high, middle and low depending on completed educational 
stage or years of education at birth of the child. The parent with the 
highest educational level was counted.  
II, III 
Immigrant parent At least one parent born outside the Nordic countries (Sweden, Finland, 
Norway or Denmark). 
IV 
Allergic heredity/ 
Parental allergic 
disease 
Mother and/or father with a doctor’s diagnosis of asthma and asthma 
medication and/or a doctor’s diagnosis of hay fever in combination with 
furred pets- and/or pollen allergy. 
I, IV 
Parental allergy Mother or father has or have had asthma, rhinitis or eczema.  III 
Parental asthma Mother or father has a history of asthma or current asthma. II 
Older siblings Older siblings at birth. II, III 
Home 
dampness or 
mould 
Current or past smell of mould and visible mould in the home in the last 
year and/or known dampness damage in the home and building 
construction or visible condensation on the inner surface of the windows 
combined with known dampness damage in the building construction. 
BAMSE. 
I 
Home 
dampness or 
mould 
Dampness, moisture or mould stains somewhere in the house during the 
child’s first year. ENRIECO. 
II, III 
Early day care 
attendance 
Child attending day care between ages one to two years.  III 
Pet ownership Furry or feathery pets in the home at birth. III 
Tobacco smoke 
exposure  
Mother smoked at least one cigarette daily at two months of age of the 
child and/or at any point of time during pregnancy. 
I 
Caesarean 
section 
Delivery by caesarean section (planned or emergency section). III 
Birth weight Continuous variable reported in grams. II 
Birth weight  Low birth weight defined as 2600 grams or below.  IV 
Gestational age Reported as weeks of gestation at delivery. II 
Preterm delivery  Delivery before gestational week 37. I 
Breast feeding 
duration 
Exclusive breast feeding for at least four months (BAMSE). Exclusive or 
partial breast feeding for at least four months (ENRIECO). 
I, II, 
III, IV 
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2.3.2 Definitions of clinical characteristics and factors related to recurrent 
abdominal pain in infancy (I) 
Exposures describing clinical characteristics and factors related to recurrent abdominal pain 
are defined in Table 3. All exposure information was based on parental reports, except for 
measurements of IgE-reactivity. 
 
Table 3 Definitions of clinical characteristics and factors related to recurrent abdominal pain in infancy 
Variable Definition Study 
Infant wheeze Having at least one episode of wheezing or whistling breathing 
sounds during the two first years of life. (Q1, Q2) 
I 
Wheeze persistency Wheezing age zero to one years, age one to two years or during 
both years. (Q1, Q2) 
I 
Wheeze episodes Wheeze less than three times or at least three times. (Q1, Q2) I 
Use of inhaled steroids  Prescribed corticosteroid inhalants due to symptoms of 
wheezing and whistling breathing sounds or forced or heavy 
breathing. (Q1, Q2) 
I 
Croup-like cough  Breathing difficulties combined with barking cough. (Q1, Q2) I 
Night cough  Troublesome cough at night. (Q1, Q2) I 
Cough during activity Cough during play, laughter or while being outdoors. (Q1, Q2) I 
Infant rhinorrhoea Runny or blocked nose with duration of at least two months 
during the last 12 months. (Q1, Q2) 
I 
Recurrent abdominal pain  Recurrent episodes of abdominal pain after the age of six 
months. (Q1, Q2) 
I 
Acute media otitis  Otitis or otosalpingitis symptoms treated with antibiotics. (Q1, 
Q2) 
I 
Diarrhoea Recurrent or long-term episodes of diarrhoea. (Q1, Q2) I 
A doctor’s diagnosis of 
food allergy 
Food allergy diagnosed by a doctor. (Q1, Q2) I 
Symptoms at ingestion of 
hens’ egg, cows’ milk or 
wheat 
Symptoms related to ingestion of hens’ egg/cows’ milk/wheat: 
asthma, itchy eyes and/or runny nose, facial oedema, urticaria, 
eczema or vomiting/diarrhoea. (Q1, Q2) 
I 
Pneumonia Pneumonia diagnosed by a doctor. (Q1, Q2) I 
Use of antibiotics
 
Having received antibiotics for any reason. (Q1, Q2) I 
Q=questionnaire. The number after corresponds to the age of the child. 
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2.3.3 Definitions of smoking (II, III) 
2.3.3.1 Prenatal smoke exposure 
Prenatal smoke exposure was defined as maternal smoking of at least one cigarette daily 
during any trimester. Information on smoking habits was collected during pregnancy or in the 
first months after delivery.  
The data used when constructing the prenatal smoke exposure variables, as well as for 
performing the dose-response analyses are described in Table 4. Since six out of eight cohorts 
had information on daily cigarette consumption from the first trimester, this trimester was 
used in the dose-response analyses in study II, except for DARC for which the amount for the 
whole pregnancy was used. The MAS cohort was excluded from dose-response assessments 
due to lack of data.  
 
Table 4 Prenatal maternal smoke exposure information 
 
 
Cohort 
Available trimester data for  
dichotomous smoke exposure 
variable (study II and III) 
Available trimester data with  
information on daily consumption  
for dose-response analysis (study II) 
ALSPAC 1
st 
, 2
nd
, 3
rd
 trimester 1
st 
 and 3
rd
 trimester 
AMICS-
Menorca 
1
st 
, 2
nd
, 3
rd
 trimester 1
st 
 and 3
rd
 trimester 
BAMSE 1
st 
, 2
nd
, 3
rd
 trimester 1st , 2nd, 3rd trimester 
DARC 
No trimester specific information. “Has 
the mother smoked during this 
pregnancy?” 
No trimester specific dose information. 
“Number of cigarettes, pipes, cigarillos or 
cigars smoked during the whole 
pregnancy”. 
GINIplus 1
st 
, 2
nd
, 3
rd
 trimester 1st , 2nd, 3rd trimester 
LISAplus 1
st 
, 2
nd
, 3
rd
 trimester 1st , 2nd, 3rd trimester 
MAS 1
st 
, 2
nd
, 3
rd
 trimester No trimester specific dose information. 
PIAMA-NHS 1
st 
, 2
nd
, 3
rd
 trimester 1
st
 and 2
nd
 trimester 
 
2.3.3.2 Postnatal smoke exposure 
Postnatal SHS exposure was defined as maternal smoking in the dwelling or near the child 
during the child’s first year of life (study II) or in infancy (study III). Any tobacco smoke 
exposure was defined as mother, father, partner or other person smoking in the dwelling or 
near the child during the child’s first year of life (study II) or in infancy (study III). In study 
II, information from the first months of life and one year was combined in the variable for 
smoke exposure in the first year of life, whereas in study III, smoke exposure information 
from the first months of life was used when constructing the variable for SHS exposure in 
infancy. 
Despite harmonization of data before analyses, some differences regarding smoke exposure 
remained. The information after harmonization is described in Table 5. 
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Table 5 Description of the available postnatal smoke exposure information used for constructing the 
exposure variables in study II and III 
 Variable for maternal smoking 
Cohort First months One year Four to six years 
ALSPAC Actively smoking, not 
limited to smoking in 
dwelling 
Actively smoking, not 
limited to smoking in 
dwelling 
Actively smoking, not 
limited to smoking in 
dwelling  
AMICS-
Menorca 
Smoking, location not 
specified  
Currently smoking at home  Currently smoking at home 
BAMSE 
Smoking at home  
Smoking, location not 
specified 
Smoking, location not 
specified 
DARC Smoking indoors  Smoking indoors  Smoking indoors 
GINIplus Smoking, not specified 
where 
- 
Smoking, not limited to 
smoking in dwelling 
LISAplus Smoking at home Smoking at home Smoking at home 
MAS Smoking at home Smoking at home Smoking at home 
PIAMA-NHS Cigarettes, pipes, cigars 
smoked in the house  
Cigarettes, pipes, cigars 
smoked in the house  
Cigarettes, pipes, cigars 
smoked in the house 
 Variable for smoke exposure by anyone 
Cohort First months One year Four to six years 
ALSPAC Mother actively smoking, 
not limited to smoking in 
the dwelling and “child in 
smoky room” 
No available information No available information 
AMICS-
Menorca 
Maternal smoking, location 
not specified and/or father 
and/or other persons 
currently smoking in the 
dwelling 
Mother, father and/or other 
persons currently smoking 
in the dwelling  
Mother, father and/or other 
persons currently smoking 
in the dwelling  
BAMSE Mother, father, siblings or 
others smoking in the 
dwelling  
Mother, father, siblings or 
others smoking in the 
dwelling 
Mother, father, siblings or 
others smoking in the 
dwelling 
DARC Mother, father, siblings or 
others smoking indoors 
Mother, father, siblings or 
others smoking indoors 
Mother, father, siblings or 
others smoking indoors 
GINIplus Mother smoking, not 
specified where, and 
someone smoking (mother 
and/or other) in the 
dwelling 
Someone smoking 
(mother and/or other) in 
the dwelling 
Someone smoking (mother 
and/or other) in the 
dwelling  
LISAplus Mother, father and/or 
others smoking in the 
dwelling  
Mother, father and/or 
others smoking in the 
dwelling  
Mother, father and/or 
others smoking in the 
dwelling 
MAS Mother, father and/or 
others smoking at home  
Mother, father and/or 
others smoking at home 
Mother, father and/or 
others smoking at home  
PIAMA-NHS Cigarettes, pipes, cigars 
smoked in the house by 
mother, father and/or other 
household members 
Cigarettes, pipes, cigars 
smoked in the house by 
mother, father and/or other 
household members 
Cigarettes, pipes, cigars 
smoked in the house by 
mother, father and/or other 
household member  
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2.3.4 Definitions of allergy related diseases and symptoms (I, II, IV) 
The definitions of allergy related diseases used in study I, II and/or IV and the outcome 
recurrent abdominal pain at age 12 years used in study IV are presented in Table 6. All 
information was based on parental reports except abdominal pain at age 12 years. 
Table 6 Definitions of allergy related diseases  
Variable Definition Study 
Asthma age one 
year 
At least three episodes of wheeze after three months of age in 
combination with treatment with inhaled glucocorticosteroids and/or 
signs of suspected hyperreactivity without concurrent upper respiratory 
infection. (Q1) 
IV 
Asthma age two 
years 
At least three episodes of wheeze after one year of age in combination 
with treatment with inhaled glucocorticosteroids and/or signs of 
suspected hyperreactivity without concurrent upper respiratory 
infection. (Q2) 
IV 
Asthma age four, 
eight and 12 years  
At least four episodes of wheeze in the last 12 months or at least one 
episode of wheeze during the same time period in combination with 
occasional or regular treatment with inhaled glucocorticosteroids. (Q4, 
Q8, Q12) 
I, IV 
Current wheeze Wheezing during the last 12 months (age four to six years). II 
Current asthma Satisfying at least two out of three of the following criteria: (i) a doctor’s 
diagnosis of asthma ever, (ii) parental-reported wheezing during the 
last 12 months, or (iii) asthma medication in the last 12 months, (age 
four to six years). 
II 
Eczema age one 
year/ Infant 
eczema 
Dry skin, itchy rashes for ≥ two weeks at specific location (face or 
arms/legs extension surfaces or arms/legs flexures or wrists/ankles 
flexures) of rash and/or doctor’s diagnosis of eczema after three 
months of age. 
I, IV 
Eczema age two 
years/Infant 
eczema 
Dry skin, itchy rashes for ≥ two weeks at specific location (face or 
arms/legs extension surfaces or arms/legs flexures or wrists/ankles 
flexures) of rash and/or doctor’s diagnosis of eczema after one year of 
age. 
I, IV 
Eczema age four 
years 
Dry skin, itchy rashes for ≥ two weeks during the last 12 months at 
specific location (face or arms/legs extension surfaces or arms/legs 
flexures or wrists/ankles flexures) of rash and/or doctor’s diagnosis of 
eczema after two years of age. 
IV 
Eczema age eight 
years 
Dry skin, itchy rashes for ≥ two weeks during the last 12 months at 
specific location (face or arms/legs flexures or wrists/ankles or neck) of 
rash and/or doctor’s diagnosis of eczema after seven years of age. 
I, IV 
Eczema age 12 
years 
Dry skin, itchy rashes during the last 12 months at specific location 
(arms/legs flexures or wrists/ankles or neck) of rash and/or doctor’s 
diagnosis of eczema after ten years of age.  
IV 
Allergic rhinitis age 
one year 
Symptoms from eye/nose following exposure to furred pets and/or 
pollen and/or doctor’s diagnosis of allergic rhinitis from the first three 
months of life. (Q1) 
IV 
Allergic rhinitis age 
two, four and eight 
years 
Symptoms from eye/nose following exposure to furred pets and/or 
pollen and/or doctor’s diagnosis of allergic rhinitis since the previous 
questionnaire. (Q2, Q4, Q8) 
I, IV 
Allergic rhinitis at 
age 12 years 
Symptoms from eye/nose following exposure to furred pets and/or 
pollen during the last 12 months and/or doctor’s diagnosis of allergic 
rhinitis from the age of ten years. (Q12) 
IV 
Table 6 continues on the next page.  
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Table 6 Definitions of allergy related diseases and symptoms, continued  
Variable Definition Study 
Food 
hypersensitivity at 
age one, two and 
four years 
Symptoms related to ingestion of a certain food at the time of the 
questionnaire: asthma, itchy eyes and/or runny nose, facial oedema, 
urticaria, eczema or vomiting/diarrhoea or avoidance of certain foods 
(at age four years) due to previous specific symptoms at ingestion. 
(Q1, Q2, Q4) 
I, IV 
Food 
hypersensitivity at 
age eight years 
Symptoms related to ingestion of a certain food at the time of the 
questionnaire: dyspnoea, oral itch, symptoms from eyes/nose, 
urticaria, eczema, vomiting and/or diarrhoea or avoidance of certain 
foods due to previous specific symptoms at ingestion. (Q8) 
IV 
Food 
hypersensitivity age 
12 years 
Symptoms related to ingestion of a certain food at the time of the 
questionnaire: asthma or allergy, cough/hoarseness, 
itchy/runny/congested nose, red itchy eyes, oedema of 
face/lips/eyelids, feeling of laryngeal/throat swollenness, urticaria, 
eczema, vomiting, diarrhoea, severe abdominal pain, pronounced 
tiredness or reduced consciousness or avoidance of certain foods due 
to previous specific symptoms at ingestion. (Q12) 
IV 
Recurrent 
abdominal pain age 
12 years 
Recurrent abdominal pain, menstrual pain excluded, experienced 
every month or more often without a diagnosis of coeliac disease or 
inflammatory bowel disease. (Q12) 
IV 
 
2.3.5 Definitions of IgE-reactivity/allergic sensitization (I, III, IV)  
2.3.5.1 IgE data in BAMSE 
The blood samples drawn at four and eight years were screened with two different IgE 
assays. Phadiatop
®
 screens for IgE antibodies to a mix of common aeroallergens: birch, 
timothy and mugwort pollen, cat, dog and horse dander, mould (C herbarum) and house dust 
mite (D pteronyssinus). Fx5
®
 screens for IgE antibodies to a mix of common food allergens: 
cow’s milk, egg white, soy bean, peanut, cod fish and wheat (ImmunoCAP™; former Phadia 
AB, now Thermo Fisher Scientific, Uppsala, Sweden).  
Sensitization was defined as IgE antibody serum levels ≥ 0.35 kUA/l. Food allergen 
sensitization data from age four years was used in study I. Information on food and 
aeroallergen sensitization at both ages was used in study IV. 
2.3.5.2 IgE data in ENRIECO 
In study III, aeroallergen sensitization was assessed in preschool (three to four years) and 
school age (six, seven or eight years). Children with IgE levels exceeding 0.35 kUA/l to the 
allergen tested were considered sensitized. The allergens were assessed together as “any 
aeroallergen sensitization” and separately in three subgroups; “pet sensitization” (cat/dog 
dander), “house dust mite sensitization” (D pteronyssinus) and “pollen sensitization” 
(tree/grass pollen). The numbers of available allergens as well as analysis methods varied as 
described in Table 7.  
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Table 7 Overview of analysis methods, ages at testing and types of allergens across cohorts 
 Any aeroallergen sensitization 
 
 
Cohort 
 
 
Analysis method 
Cut-off value  
for 
sensitization 
Child’s 
age at 
testing 
Pet 
allergens 
House dust 
mite 
allergens 
Pollen 
allergens 
ALSPAC 
SPT (ALK-ABELLÒ, 
Hoersholm, 
Denmark) 
Mean wheal 
diameter >2 
mm 
7 y 
Cat 
dander 
Dpt 
Grass pollen 
mix: Bermuda, 
Kentucky Blue, 
timothy 
AMICS-
Menorca 
UniCap (Pharmacia, 
Morris Plains, NJ) 
>0.35 kUA/l 4 y 
Cat 
dander 
Dpt 
Grass pollen 
mix 
Olive tree 
BAMSE ImmunoCAP (Phadia 
AB/Thermo Fisher, 
Uppsala, Sweden) 
>0.35 kUA/l 4 y, 8 y 
Cat, dog 
dander 
Dpt Timothy, birch, 
mugwort 
DARC Magic Lite SQ allergy 
screen (ALK-
ABELLÒ, Hoersholm, 
Denmark)  
 
>1.43 sU/l 3 y 
Cat, dog 
dander 
Dpt Timothy, birch, 
mugwort 
 ImmunoCAP (Phadia 
AB/Thermo Fisher, 
Uppsala, Sweden) 
>0.35 kUA/l 6 y 
Cat, dog 
dander 
Dpt Timothy, birch, 
mugwort 
GINIplus CAP-RAST FEIA 
(Pharmacia 
Diagnostics, 
Freiburg, Germany) 
>0.35 kUA/l 6 y 
Cat,dog 
dander 
Dpt Rye, birch, 
mugwort 
LISAplus CAP-RAST FEIA 
(Pharmacia 
Diagnostics, 
Freiburg, Germany) 
>0.35 kUA/l 6 y 
Cat, dog 
dander 
Dpt Timothy, birch, 
mugwort 
MAS ImmunoCAP (Phadia 
AB/Thermo Fisher, 
Uppsala, Sweden) 
>0.35 kUA/l 3 y, 7 y 
Cat, dog 
dander 
Dpt Timothy, birch  
PIAMA-
NHS 
RAST-like method 
(Sanquin 
Laboratories, 
Amsterdam, The 
Netherlands). 
>0.35 kUA/l 4 y, 8 y 
Cat, dog 
dander 
Dpt Cocksfoot, birch  
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2.4 STATISTICAL ANALYSES 
Statistical analyses were performed with the STATA statistical software, version 11.2 
and13SE, (StataCorp, College Station, Texas, USA). 
Prevalence  
Prevalence of outcomes, exposures and baseline characteristics were expressed as 
percentages of the total number of available observations at the time of assessment.  
Confidence intervals  
Proportions with 95% confidence intervals were calculated for baseline characteristics, 
allergy-like symptoms and selected exposures between the originally enrolled children and 
the children included in the respective study. Proportions were compared between groups in 
order to evaluate differences of importance for selection and generalizability. Non-
overlapping confidence intervals were considered significantly different.  
The Chi-square test of independence 
Comparisons of observed and expected proportions were made by the Chi-square test. This 
method was used for evaluating selection bias by comparing the study populations with the 
original cohort populations with regard to certain factors, at confounder assessment, and for 
detecting differences between groups with regard to outcomes and exposures. 
P for trend 
P for trend was calculated for categorical variables, assuming equidistant categories in study 
IV. 
Proportional Venn-diagrams 
Proportional Venn-diagrams were calculated for asthma, eczema and allergic rhinitis at age 
eight years separately for infant wheezers and non-wheezers as well as for markers of 
increased wheeze severity in study I. Venn-diagrams give a more visual overview of 
associations than a two-by-two table for example. 
Logistic regression 
Logistic regression was used to calculate odds ratios with 95% confidence intervals as 
estimates of relative risk/associations. Two multivariate logistic regression models were used 
where different adjustment variable combinations were included in study I and IV. In the first 
model, covariates describing background characteristics were included as adjustment 
variables. In the second model, further adjustments for concurrent allergy-related diseases or 
other symptoms associated with exposure or outcome were included in order to assess 
independent associations of the exposure under study. In the first out of two analysis stages, 
cohort-specific crude and adjusted estimates were calculated by logistic regression also in 
study II and III.  
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Confounder assessment was done by testing potential confounding factors in the logistic 
regression models in a univariate and stepwise manner. Besides the confounders chosen due 
to subject-matter knowledge, covariates that resulted in an OR change of more than 5% 
(study I, II, III) or 10% (study IV) when added to the regression models were considered 
confounders. 
Meta-analysis  
The cohort-specific ORs obtained by logistic regression were combined in a random effects 
meta-analysis model (study II and III). This model considers both within-cohort and between-
cohort variation
134
 as opposed to fixed effects models where the contribution of each 
participating study to the combined OR estimate (weighting) depends mainly on study size.  
Dose-response analysis 
Dose-response associations between maternal cigarette consumption during the first trimester 
and preschool wheeze and asthma were assessed in study II. In study III we performed dose-
response analyses between the amount of cigarettes smoked daily by the mother or anyone in 
infancy and IgE-reactivity to aeroallergens. Before analyses, non-linearity was explored by 
testing the null hypothesis that the coefficient of the quadratic exposure term was equal to 
zero. This was done in each individual cohort and after combining data by random effects 
methods. A flexible logistic model was applied for each cohort using a maximum likelihood 
method. In a second step, the obtained estimated regression coefficients and their 
variance/covariance matrices were applied in a multivariate random effects meta-analysis 
model.  
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3 RESULTS 
3.1 CHILDHOOD ASTHMA – RISK FACTORS AND CONSEQUENCES  
3.1.1 Wheezing in infancy and school age asthma (I) 
Among the 3,251 included children, 823 (25.3%) wheezed at least once during the two first 
years of life. Among these infant wheezers, 14.1% (116 children) had asthma at age eight 
years, compared to 3.7% (90 children) of the 2,428 infant non-wheezers (p<0.001). After 
adjustments for sex, tobacco smoke exposure and indoor dampness/mould, the risk of asthma 
at age eight years was almost fourfold among infant wheezers compared to infant non-
wheezers, OR 3.68 (95% CI 2.74-4.96). 
Severity of wheeze and asthma  
The risk of asthma at age eight years increased with the number of wheezing episodes. For 
the 469 children that wheezed at least three times the adjusted OR for asthma at age eight 
years was 3.41 (95% CI 2.09-5.56), using the 354 children with less than three episodes of 
wheeze during the first two years of life as reference, Table 8. 
Infant wheezers with inhaled steroid medication had a higher risk of school age asthma. 
About 30.5% of the 151 infant wheezers with prescribed inhaled steroids had school age 
asthma, compared to 10.4% among the 672 wheezers without this medication. The adjusted 
OR for school age asthma was 3.42 (95% CI 2.20-5.32) for infant wheezers with steroid 
inhalants compared to wheezers without steroid inhalants, Table 8.  
The risk of asthma also differed between infant wheezers depending on time of wheezing 
debut and persistency of wheezing symptoms. The 249 infants that wheezed during the first 
and second year of life, and the 353 infants with a wheeze debut during the second year of 
life had a higher risk of school age asthma (21.3% and 14.4% developed asthma, 
respectively). This is to be compared to the 218 infants wheezing only during the first year 
out of which only 5.0% had asthma in school age. Using these infants as reference, the 
adjusted OR for asthma in school age for infants that wheezed both years was 5.11 (95% CI 
2.51-10.41), and for infants with wheeze debut in the second year, 3.43 (95% CI 1.69-6.96), 
Table 8. 
The characteristics above describing an increased severity of wheeze, overlapped 
substantially. Over 96% of the infant wheezers with at least three wheezing episodes had also 
used steroid inhalants or had wheezed both during the first and second year of life. 
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Table 8 Associations between sex, allergic heredity, characteristics of infant wheeze, and early 
comorbidity in relation to asthma at age eight years among children with infant wheeze, (N=823) 
    Asthma at age 8 years 
    N n % aOR
 
(95 % CI)
*
 
Total    823 116 14.1  
Sex
†
  Girl  341 46 13.5 1.00 (reference) 
  Boy  482 70 14.5 1.10 (0.73-1.67) 
Allergic heredity
‡ 
 No  508 59 11.6 1.00 (reference) 
  Yes  302 54 17.9 1.53 (1.02-2.30) 
Wheeze persistency  First year of life only  218 11 5.0 1.00 (reference) 
  Second
 
year only  353 51 14.4 3.43 (1.69-6.96) 
  Both years  249 53 21.3 5.11 (2.51-10.41) 
Wheeze episodes  <2 episodes  354 24 6.8 1.00 (reference) 
  >3 episodes  469 92 19.6 3.41 (2.09-5.56) 
Use of inhaled steroids  No  672 70 10.4 1.00 (reference) 
  Yes  151 46 30.5 3.42 (2.20-5.32) 
Infant eczema  No  574 62 10.8 1.00 (reference) 
  Yes  249 54 21.7 2.31 (1.52-3.49) 
Infant rhinorrhoea  No  726 98 13.5 1.00 (reference) 
  Yes  97 18 18.6 1.32 (0.75-2.34) 
Croup-like cough  No  455 54 11.9 1.00 (reference) 
  Yes  368 62 16.9 1.45 (0.96-2.18) 
Night cough  No  73 12 16.4 1.00 (reference) 
  Yes  748 103 13.8 0.73 (0.38-1.43) 
Cough during activity  No  277 29 10.5 1.00 (reference) 
  Yes  543 87 16.0 1.53 (0.97-2.44) 
Acute media otitis  No  368 48 13.0 1.00 (reference) 
  Yes  453 67 14.8 1.07 (0.71-1.61) 
Recurrent abdominal pain  No  744 97 13.0 1.00 (reference) 
  Yes  77 19 24.7 2.33 (1.30-4.16) 
*Adjustment made for sex, heredity, dampness or mould at home, tobacco smoke exposure and maternal age. 
†
Adjustment made for all potential confounders besides sex. 
‡
Adjustment made for all potential confounders besides heredity. 
aOR, adjusted odds ratio; CI, confidence interval. 
 
 
Wheeze, allergic heredity and asthma 
Allergic heredity was more common among wheezing infants compared to non-wheezers, the 
proportions with allergic parents being 37.3% compared to 28.0% in the respective groups 
(p<0.001). Allergic heredity was associated with asthma at age eight years among infant 
wheezers, adjusted OR 1.53 (95% CI 1.02-2.30), Table 8.  
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Wheeze, comorbidity and asthma 
Allergic comorbidity such as eczema and food hypersensitivity as well as symptoms from the 
respiratory tract (rhinorrhoea and different kinds of cough) were more common among infant 
wheezers compared to non-wheezers, (p<0.001). Among the infant wheezers, concomitant 
eczema was associated with higher odds of asthma at age eight years, adjusted OR 2.31 (95% 
CI 1.52-3.49). This was also true for food hypersensitivity, adjusted OR 1.93 (95% CI 1.22-
3.04) and for doctor’s diagnosed food allergy, adjusted OR 2.66 (95% CI 1.52-4.63). 
Furthermore, symptoms after ingestion of wheat and hens’ egg was associated with asthma at 
age eight years, adjusted OR 3.15 (95% CI 1.08-9.20) and 2.40 (95% CI 1.15-5.00). No 
associations between infant rhinorrhoea or cough among infant wheezers and asthma at age 
eight years were seen, Table 8. 
Wheeze, recurrent abdominal pain and asthma 
Recurrent abdominal pain between six months and two years of life was more frequent 
among the infant wheezers. Among these children, 77 (9.4%) suffered from recurrent 
abdominal pain compared to 127 (5.2%) among the children without wheeze (p<0.001). 
Infant wheezers with parental reported recurrent abdominal pain had a higher risk of asthma 
at age eight years, adjusted OR 2.33 (95% CI 1.30-4.16), Table 8. Significant associations 
remained between recurrent abdominal pain among infant wheezers and asthma at age eight 
years after additional adjustment for factors related to abdominal pain in infancy, adjusted 
OR 2.31 (95% CI 1.21-4.43). 
Combining risk factors in infant wheezers 
Allergic heredity, increased severity of wheeze (at least three episodes of wheeze), infant 
eczema and recurrent abdominal pain were combined into four groups depending on number 
of coexisting risk factors. For the 92 wheezers with three or four risk factors, 38.0% had 
asthma at age eight years compared to 7.3% among the 151 wheezers with no risk factors 
who wheezed less than three times in infancy. In the group of wheezers with one (329 
children) or two risk factors (236 children), 8.8% and 16.1% had asthma at age eight years, 
respectively. 
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ADDITIONAL RESULTS (I) 
 
When does asthma start in infants with severe wheeze? 
It might be argued that the infants with increased severity of wheeze already had asthma 
before age two years and not early asthma-like respiratory symptoms, therefore the 
prevalence of doctor’s diagnosis of asthma and asthma according to definition at age one and 
two years (the definition is described in Table 6, page 25) were assessed among children up 
to two years of age with any wheeze as well as among the subgroups of wheezers with 
different characteristics of increased severity of wheeze in the two first years of life. The 
overlaps between infant wheeze and severity subgroups and these two definitions of asthma 
in infancy are described in Table 9.  
About 20-30% of the 823 infant wheezers had received a diagnosis of asthma or fulfilled the 
definition of asthma at the same age, whereas the majority of infants with more than three 
episodes of wheeze, inhaled steroid use, or persistent wheeze had asthma according to 
definition before age two years. Besides for steroid inhalant use, the overlap was less with 
regard to a doctor’s diagnosis of asthma in the subgroups with increased severity of wheeze.  
 
Table 9 Proportions with doctor’s diagnosis of asthma or asthma according to definition among infant 
wheezers and subgroups with increased severity of wheeze in the two first years of life  
 Any wheeze  
>1 episodes 
 
N=823 
Wheeze 
 >3 episodes 
 
N=469 
Use of inhaled  
steroids 
 
N=151 
Persistent wheeze  
(1
st
 and 2
nd
 yr) 
 
N=249 
 n (%) n (%) n (%) n (%) 
A doctor’s diagnosis of asthma in the first two years of life 
No 644 (78.3%) 314 (66.9%) 33 (21.9%) 146 (58.6%) 
Yes 178 (21.7%) 155 (33.1%) 118 (78.1%) 103 (41.4%) 
Asthma according to definition in the first two years of life  
No  543 (66.5%) 190 (40.9%) 15 (9.9%) 97 (39.4%) 
Yes 274 (33.5%) 274 (59.1%) 136 (90.1%) 149 (60.6%) 
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Strengthening the definition of wheeze 
The results after restricting the analyses in study I to infants that wheezed at least three times 
during the two first years of life are displayed in Table 10 and 11. The same independent risk 
factors remained in these children as in the infant wheezers. In addition, having received a 
doctor’s diagnosis of food allergy before age two years was also an independent risk factor 
for school age asthma. 
Table 10 Associations between sex, allergic heredity, characteristics of infant wheeze and early 
comorbidity in relation to asthma at age eight years among children with at least three episodes of 
wheeze during the two first years of life (N=469) 
    Asthma at age 8 years 
    N n % aOR
 
(95 % CI)* 
Total    377 92 19.6  
Sex†  Girl  189 31 20.1 1.00 (reference) 
  Boy  280 54 19.3 0.91 (0.56-1.48) 
Allergic heredity‡
 
 No  284 41 14.4 1.00 (reference) 
  Yes  178 49 27.5 2.06 (1.27-3.34) 
Wheeze persistency  1
st
 year of life only  72 2 2.8 1.00 (reference) 
  2
nd 
year only  163 36 22.1 9.12 (2.11-39.45) 
  Both years  232 53 22.8 8.91 (2.09-37.99) 
Use of inhaled steroids  No  333 51 15.3 1.00 (reference) 
  Yes  136 41 30.1 2.07 (1.26-3.40) 
Infant eczema  No  326 45 13.8 1.00 (reference) 
  Yes  143 47 32.9 3.23 (1.95-5.33) 
Infant rhinorrhoea  No  400 76 19.0 1.00 (reference) 
  Yes  69 16 23.2 1.16 (0.61-2.19) 
Croup-like cough  No  251 41 16.3 1.00 (reference) 
  Yes  218 51 23.4 1.39 (0.86-2.25) 
Night cough  No  30 10 33.3 1.00 (reference) 
  Yes  438 82 18.7 0.42 (0.18-0.95) 
Cough during activity  No  125 22 17.6 1.00 (reference) 
  Yes  343 70 20.4 0.99 (0.57-1.72) 
Acute media otitis  No  194 34 17.5 1.00 (reference) 
  Yes  274 51 20.8 1.08 (0.66-1.77) 
Recurrent abdominal pain  No  420 76 18.1 1.00 (reference) 
  Yes  49 16 32.6 2.26 (1.14-4.47) 
*Adjustment made for sex, heredity, dampness or mould at home, tobacco smoke exposure and maternal age. 
†Adjustment made for all potential confounders besides sex. 
‡Adjustment made for all potential confounders besides heredity. 
aOR, adjusted odds ratio; CI, confidence interval. 
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Table 11 Association between recurrent abdominal pain and factors associated with recurrent 
abdominal pain during the first two years of life in relation to asthma at age eight years among children 
with at least three episodes of wheeze during the two first years of life. Results expressed as adjusted 
odds ratios with 95 % confidence intervals, (N=469) 
  Asthma at age 8 years 
     Model 1 Model 2 
  N n % aOR
 
(95 % CI)* aOR
 
(95 % CI) † 
Recurrent abdominal pain No 420 76 18.1 1.00 (reference) 1.00 (reference) 
 Yes 49 16 32.6 2.26 (1.14-4.47) 2.69 (1.21-5.96) 
A doctor’s diagnosis of food  No 722 72 17.1 1.00 (reference) 1.00 (reference) 
allergy Yes 47 20 42.5 3.69 (1.88-7.22) 4.08 (1.46-11.38) 
Infant eczema No 326 45 13.8 1.00 (reference) 1.00 (reference) 
 Yes 143 47 32.9 3.23 (1.95-5.33) 2.96 (1.67-5.23) 
Food hypersensitivity No 356 61 17.1 1.00 (reference) 1.00 (reference) 
 Yes 99 28 28.3 1.70 (0.99-2.94) 0.61 (0.25-1.50) 
Symptoms at ingestion of  No 421 78 18.5 1.00 (reference) 1.00 (reference) 
cow’s milk Yes 48 14 29.2 1.69 (0.83-3.42) 0.71 (0.24-2.08) 
Symptoms at ingestion of No 456 86 13.6 1.00 (reference) 1.00 (reference) 
wheat Yes 13 6 46.1 2.78 (0.84-9.24) 1.93 (0.42-8.81) 
Diarrhoea  No 338 68 20.1 1.00 (reference) 1.00 (reference) 
 Yes 131 24 18.3 0.83 (0.48-1.43) 0.57 (0.30-1.07) 
* Model 1: Adjustment made for sex, heredity, dampness or mould at home, tobacco smoke exposure and 
maternal age. 
†Model 2: Besides adjustment as in model a, each multivariate logistic regression model consists of recurrent 
abdominal pain, doctor’s diagnosis of food allergy, infant eczema, food hypersensitivity, symptoms at ingestion of 
cows’ milk and wheat, and diarrhoea. 
aOR, adjusted odds ratio; CI, confidence interval. 
 
What about the non-wheezers? 
Table 12 displays the assessment of similar risk factors for school age asthma as for the infant 
wheezers among the 2,428 infants that did not wheeze during the first two years of life. 
Allergic heredity, infant eczema, croup-like cough, cough during activity, food allergy 
diagnosis and food hypersensitivity were characteristics and comorbidities that were 
associated with asthma at age eight years in this group. After additional adjustment for all 
comorbidities except the one under study, allergic heredity, infant eczema, croup-like cough 
and food hypersensitivity remained independent risk factors for school age asthma among the 
children without parental-reported symptoms of wheeze during infancy, (data not shown).  
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Table 12 Associations between sex, allergic heredity and early comorbidity in relation to asthma at 
age 8 years among children without infant wheeze, (N=2,428) 
    Asthma at age 8 years 
    N n % aOR
 
(95 % CI)* 
Total    2428 90 3.7  
Sex†  Girl  1265 42 3.3 1.00 (reference) 
  Boy  1163 48 4.1 1.31 (0.85-2.00) 
Allergic heredity‡
 
 No  1737 41 2.4 1.00 (reference) 
  Yes  676 49 7.2 3.22 (2.10-4.93) 
Use of inhaled steroids  No  2408 89 3.7 1.00 (reference) 
  Yes  20 1 5.0 1.07 (0.14-8.31) 
Infant eczema  No  1856 49 2.6 1.00 (reference) 
  Yes  572 41 7.2 2.47 (1.60-3.82) 
Infant rhinorrhoea  No  2294 85 3.7 1.00 (reference) 
  Yes  134 5 3.7 0.87 (0.34-2.21) 
Croup-like cough  No  2098 329 3.2 1.00 (reference) 
  Yes  329 23 7.0 2.14 (1.30-3.52) 
Night cough  No  748 19 2.5 1.00 (reference) 
  Yes  1677 71 4.2 1.55 (0.92-2.60) 
Cough during activity  No  1460 42 2.9 1.00 (reference) 
  Yes  967 48 5.0 1.64 (1.07-2.52) 
Acute media otitis  No  1365 48 3.5 1.00 (reference) 
  Yes  1050 41 3.9 1.09 (0.71-1.68) 
Recurrent abdominal pain  No  2297 80 3.5 1.00 (reference) 
  Yes  127 9 7.1 1.99 (0.96-4.10) 
Dr diagnosis of food allergy  No  2881 73 3.2 1.00 (reference) 
  Yes  142 16 11.3 3.16 (1.76-5.66) 
Food hypersensitivity  No  2057 59 2.9 1.00 (reference) 
  Yes  319 29 9.1 3.40 (2.13-5.44) 
*
Adjustment made for sex, heredity, dampness or mould at home, tobacco smoke exposure and maternal age. 
†
Adjustment made for all potential confounders besides sex. 
‡
Adjustment made for all potential confounders besides heredity. 
aOR, adjusted odds ratio; CI, confidence interval. 
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3.1.2 Maternal smoking during pregnancy and preschool asthma (II) 
The associations between exposure to maternal tobacco smoking during pregnancy and 
preschool wheeze and asthma were assessed in a pooled analysis including 21,600 European 
children from eight birth cohorts. An overview of periods of recruitment, numbers and 
proportions of included children from each cohort are provided in Table 1, page 19.  
The prevalence of wheeze at age four to six years ranged from 6.2% to 14.7% across cohorts. 
On average, 10.4% of the children had wheezed during the last 12 months in preschool age. 
The corresponding prevalence range for preschool asthma was 3.4% to 13.7%, with an 
average proportion of 6.6% for all cohorts combined.  
The children were allocated into four disjunctive categories depending on maternal smoke 
exposure status during pregnancy and in the first year after delivery, Table 13. 
 
Table 13 Prevalence of maternal smoking during pregnancy and during the first year after delivery in 
eight European birth cohorts comprising 21,600 children included in the pooled analyses 
  
No smoking 
(reference) 
 
Smoking during 
pregnancy only 
 
Smoking during the 
first year only 
Smoking during 
pregnancy 
and first year 
Birth cohort n (%)
*
 n (%)
†
 n (%)
‡
 n (%)
§
 
ALSPAC 5460 (71.2) 157 (2.1) 407 (5.3) 1,584 (20.8) 
AMICS-Menorca 268 (60.8) 28 (6.3) 12 (2.7) 133 (30.2) 
BAMSE 3,051 (83.1) 93 (2.5) 153 (4.2) 376 (10.2) 
DARC 315 (63.6) 35 (7.1) 17 (3.4) 128 (25.9) 
GINIplus 3,159 (83.3)
**
 123 (3.2)
**
 137 (3.6)
**
 375 (9.9)
** 
LISAplus 1,421 (80.7) 106 (6.0) 67 (3.8) 166 (9.4) 
MAS 561 (63.6) 18 (2.0) 127 (13.9) 188 (20.6) 
PIAMA-NHS 2,291 (78.1) 175 (6.0) 56 (1.9) 413 (14.1) 
Total 16,526 (76.5) 735 (3.4) 976 (4.5) 3,363 (15.6) 
*
No maternal smoking during pregnancy or in the first year after delivery. 
†
 Maternal smoking of at least one cigarette daily during any time of pregnancy, but no smoking during the first 
year after delivery. 
‡
 No maternal smoking during pregnancy, but maternal smoking during the first year after delivery. 
§
 Maternal smoking of at least one cigarette daily during any time of pregnancy and during the first year after 
delivery. 
**
Information on maternal smoking collected 4 months after delivery. 
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We found 735 (3.4%) children exposed to maternal tobacco smoke during pregnancy but not 
during the first year of life, Table 13. This group of in utero exposed children had an 
increased risk of wheeze and asthma in preschool age, with combined adjusted ORs of 1.39 
(95% CI 1.08-1.77) for wheeze, and 1.65 (95% CI 1.18-2.31) for asthma, Figure 3. 
Adjustments were made for sex, parental education, birth weight, parental asthma and older 
siblings. 
Excluding children exposed to tobacco smoke not only by the mother but also by the father or 
other persons during the first year resulted in similar combined adjusted ORs, 1.68 (95% CI 
1.26-2.25) for preschool wheeze and 1.75 (95% CI 1.16-2.63) for asthma. Further restriction 
to children that were not exposed to maternal tobacco smoke at the time of outcome 
assessment resulted in combined adjusted ORs of 1.63 (95% CI 1.25-2.12) for wheeze and 
1.95 (95% CI 1.34-2.85) for asthma. Similar results were observed when children exposed to 
tobacco smoke by any persons (i.e. not only to maternal smoking) in the first postnatal year 
and in preschool age were excluded, data not shown.  
There was a significant dose-response effect between maternal smoking during the first 
trimester and risk of preschool wheeze and asthma. Every five cigarette increase in daily 
consumption conferred an adjusted OR of 1.18 (95% CI 1.02-1.38) for preschool wheeze and 
1.23 (95% CI 1.03-1.47) for asthma. These analyses were restricted to children whose 
mothers did not smoke during the first postnatal year. 
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Figure 3A and B Associations between maternal smoking during pregnancy only (no maternal 
smoking during the first year of life) in relation to preschool wheeze (3A) and asthma (3B). Cohort-
specific odds ratios (ORs) and 95% confidence intervals (CIs) were obtained by logistic regression 
adjusted for sex, parental asthma, parental education, siblings and birth weight. Combined ORs and 
95% CIs derived by random effects methods. N=total number of children in each cohort, n=number of 
exposed cases in each cohort. ALSPAC (UK) lacked information on doctor’s diagnosis of asthma and 
was not included in the analyses of current asthma. 
Figure 3A 
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The 3,363 children (15.6%) exposed to maternal tobacco smoke during pregnancy as well as 
in the first year after delivery also had a higher risk of preschool wheeze and asthma, with 
combined adjusted ORs of 1.25 (95% CI 1.09-1.43) and 1.30 (95% CI 1.00-1.68), 
respectively.  
There was no increased risk for preschool wheeze or asthma for the 976 children (4.5%) 
exposed to maternal tobacco smoke in the first year after delivery but not during pregnancy, 
with combined adjusted ORs for preschool wheeze 0.91 (95% CI 0.71-1.17) and 1.20 (95% 
CI 0.84-1.71) for preschool asthma. 
 
ADDITIONAL RESULTS (II)  
Is the dose-response effect a marker of continued smoking throughout 
pregnancy? 
We investigated if the observed dose-response effect based on information on amount of 
smoked cigarettes from the first trimester was a marker of continued smoking throughout 
pregnancy by further restricting the dose-response analyses to only comprise children that 
were not exposed to maternal tobacco smoke during the third trimester as well as during the 
first year after delivery. These analyses resulted in adjusted ORs of 1.30 (95% CI 0.94-1.79) 
for preschool wheeze and 1.44 (95% CI 1.14-1.81) for preschool asthma for every five 
cigarette increment in daily consumption during the first trimester. 
Exclusion of birth weight as a confounder 
We adjusted for birth weight as a confounder in study II. However, birth weight may be a 
mediator and in that case we should not have adjusted for it. Exclusion of birth weight as 
adjustment variable resulted in combined ORs (adjusted for sex, parental asthma, parental 
education and siblings) of 1.38 (95% CI 1.10-1.74) and 1.62 (95% CI 1.18-2.23) for maternal 
smoking during pregnancy but not in the first year and preschool wheeze and asthma, 
respectively. No significant heterogeneity was present between studies.  
Potential interaction between pre- and postnatal smoke exposure 
Pre- and postnatal smoke exposure may interact in an independent way that influences 
wheeze or asthma development. The pooled P-value for interaction between maternal 
smoking during pregnancy and maternal smoking during the first year after delivery was 
0.817 for preschool wheeze as outcome. The corresponding pooled P-value for interaction for 
preschool asthma as outcome was 0.198. 
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3.1.3 Childhood asthma and recurrent abdominal pain (IV) 
The association between allergy-related diseases and recurrent abdominal pain was examined 
in study IV. At age 12 years, 237 (9.1%) children reported having abdominal pain at least 
once every month. Of these, 15 (6.6%) fulfilled the definition of asthma at age one year, 
compared to 82 (3.5%) of the 2,373 children without abdominal pain, p=0.02.  
In logistic regression analyses, asthma during the first and second year of life was 
significantly associated with recurrent abdominal pain at age 12 years, with ORs adjusted for 
sex of 2.26 (95% CI 1.27-4.04) and 1.81 (95% CI 1.07-3.05), respectively. Asthma at age 12 
years was significantly associated with recurrent abdominal pain at the same age, with an OR 
adjusted for sex of 2.15 (95% CI 1.35-3.43), Figure 4A. However, asthma did not remain an 
independent risk factor for concurrent abdominal pain at age 12 years after additional 
adjustment for other coexisting allergy-related diseases, OR 1.66 (95% CI 0.96-2.85), Table 
14. 
 
Figure 4 Allergy-related diseases during childhood and recurrent abdominal pain at age 12 years. 
Age-specific associations between A) asthma, B) allergic rhinitis, C) eczema, and D) food 
hypersensitivity and recurrent abdominal pain at age 12 years. Results are presented as adjusted 
odds ratios (OR) with 95% confidence intervals (95% CI), adjusted for sex. 
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“Total allergy burden” and recurrent abdominal pain 
The risk of abdominal pain at age 12 years increased with increasing number of coexisting 
allergy related symptoms (asthma, allergic rhinitis, eczema and food hypersensitivity), P for 
trend <0.001. All allergy-related symptoms were significantly associated with concurrent 
abdominal pain at age 12 years, Figure 4 and Table 14 (Model I). After adjustment not only 
for sex but for all allergy-related symptoms except the one under study, the significant 
association remained for eczema, OR 1.86 (95% CI 1.27-2.74) and food hypersensitivity, OR 
2.00 (95% CI 1.42-2.79). This also held true for children with a doctor’s diagnosis of food 
allergy combined with reported food hypersensitivity and positive food sensitization at age 
eight years, OR 2.16 (95% CI 1.02-4.57), Table 14 (Model II). 
 
Table 14 Allergy-related diseases at different ages and risk of recurrent abdominal pain  
at 12 years 
 
Exposure 
OR (95%CI) 
Model I
1
 
OR (95%CI) 
Model II
2
 
Asthma 1yr 2.26 (1.27-4.04) 2.33 (1.29-4.24) 
Asthma 2yrs 1.81 (1.07-3.05) 1.83 (1.07-3.13) 
Asthma 4yrs 1.29 (0.75-2.21) 1.36 (0.77-2.41) 
Asthma 8yrs 1.23 (0.71- 2.15) 0.93 (0.50-1.74) 
Asthma 12yrs 2.15 (1.35-3.43)  1.66 (0.96-2.85) 
Allergic rhinitis 1yr 1.05 (0.50-2.20)  0.81 (0.37-1.76) 
Allergic rhinitis 2yrs 1.08 (0.55-2.12)  0.88 (0.44-1.77) 
Allergic rhinitis 4yrs 1.10 (0.69-1.75)  1.10 (0.66-1.84) 
Allergic rhinitis 8yrs 1.25 (0.84-1.85)  0.87 (0.54-1.39) 
Allergic rhinitis 12yrs 1.58 (1.15-2.17)  0.96 (0.65-1.43) 
Eczema 1yr 1.05 (0.71-1.55) 0.94 (0.62-1.42) 
Eczema 2yrs 1.35 (0.98-1.88) 1.24 (0.88-1.75) 
Eczema 4yrs 1.31 (0.95-1.81) 1.28 (0.89-1.85) 
Eczema 8yrs 1.44 (0.99-2.11) 1.32 (0.89-1.96) 
Eczema 12yrs 2.09 (1.49-2.92) 1.86 (1.27-2.74) 
Food hypersensitivity 1yr 1.45 (0.94-2.24) 1.48 (0.94-2.33) 
Food hypersensitivity 2yrs 1.40 (0.90-2.19) 1.27 (0.80-2.03) 
Food hypersensitivity 4yrs 1.48 (0.98-2.24) 1.26 (0.80-1.99) 
Food hypersensitivity 8yrs 1.82 (1.28-2.58) 1.80 (1.20-2.69) 
Food hypersensitivity 12yrs 2.35 (1.74-3.17) 2.00 (1.42-2.79) 
IgE food allergy, 4yrs3
 
 3.34 (1.64-6.82) 2.19 (0.91-5.26) 
IgE food allergy, 8yrs3
 
 2.63 (1.50-4.61) 2.16 (1.02-4.57) 
1
Model I: Logistic regression adjusted for sex.  
2 
Model II: Logistic regression adjusted for sex and all other allergic diseases than the exposure under study. 
Exposure and adjustment variables from the same age of the child. 
3
Food hypersensitivity and sensitisation to food and a doctor’s diagnosis of food allergy.
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ADDITIONAL RESULTS (IV) 
Recurrent abdominal pain in the two first years of life and at age 12 years 
Since children reporting recurrent abdominal pain at age 12 years may have had recurrent 
abdominal pain already in the two first years of life, we compared the prevalence of recurrent 
abdominal pain at age 12 years among children with and without recurrent abdominal pain in 
infancy. The prevalence of recurrent abdominal pain at age 12 years was somewhat higher 
among children who had parental reported abdominal pain in the two first years of life 
compared to those who did not (14% vs. 8%, p=0.009). However, most (86%) of the children 
with parental reported recurrent abdominal pain in the two first years of life did not report 
recurrent abdominal pain at age 12 years.  
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3.2 CHILDHOOD IgE- REACTIVITY – RISK FACTORS AND CONSEQUENCES 
3.2.1 Early second hand tobacco smoke exposure and aeroallergen 
sensitization (III) 
We investigated the association between maternal smoking during pregnancy and infancy and 
pet, house dust mite and pollen sensitization in the offspring up to age eight years. The 
analyses were based on 14,613 children from eight European birth cohorts. An overview of 
periods of recruitment and numbers of included children for each cohort are provided in 
Table 1, page 19.  
In preschool age, 4,204 children from five cohorts were included in the pooled analyses. The 
prevalence of aeroallergen sensitization ranged from 12.5% to 18.9%. Sensitization to pollen 
dominated in most cohorts, followed by house dust mite sensitization.  
Maternal smoking during pregnancy was not associated with any aeroallergen sensitization, 
with combined ORs 1.04 (95% CI 0.83-1.31) in preschool age and 1.05 (95% CI 0.85-1.30) 
in school age. Moderate heterogeneity was present at school age, (I
2
=62.2%, p=0.015). We 
observed no associations between maternal smoking during pregnancy and sensitization in 
preschool or school age for any of the subgroups pets, house dust mite or pollen (data not 
shown). 
No significant associations were observed between maternal or any SHS exposure in infancy 
and aeroallergen sensitization in preschool age, with combined adjusted ORs 1.07 (95% CI 
0.82-1.40) and 0.90 (95% CI 0.65-1.25), respectively, Figure 5. Moderate heterogeneity was 
present between studies in the assessment of any SHS exposure (I
2
=47.4%, p=0.107). 
When aeroallergen subgroups were analysed separately, there was a statistically significant 
association between any SHS exposure and pet sensitization in preschool age, combined 
adjusted OR 1.40 (95% CI 1.02-1.90). However, the association was non-significant for 
maternal SHS exposure, combined adjusted OR 1.38 (95% CI 0.92-2.06). No significant 
associations were observed for house dust mite or pollen sensitization in preschool age (data 
not shown). 
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Figure 5 Associations between maternal (5A) and any (5B) SHS exposure in infancy and any 
aeroallergen sensitization in preschool age. Individual ORs with 95% CI obtained by logistic 
regression adjusted for sex, parental allergy and parental education. Overall OR with 95% CI derived 
by random effects methods. n=total number of exposed cases, N=total number of included children. 
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In school age, 13,279 children from seven cohorts were included in the analyses. The 
prevalence of school age aeroallergen sensitization was higher compared to in preschool age, 
with prevalence’s ranging from 14.8% to 34.5% across cohorts. Again, pollen was the 
dominating sensitizing aeroallergen, followed by house dust mite sensitization. 
There were no significant associations between maternal or any SHS exposure in infancy and 
any aeroallergen sensitization in school age, with combined adjusted ORs of 0.99 (95% CI 
0.80-1.23) and 1.00 (95% CI 0.85-1.18), respectively. Moderate heterogeneity was present 
between studies (I
2
=55.3%, p=0.037 and I
2
=52.1%, p=0.051), Figure 6. Similar non-
significant associations were seen when assessing the three aeroallergen subgroups as 
separate outcomes, data not shown. 
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Figure 6 Associations between maternal (6A) and any (6B) SHS exposure in infancy and any 
aeroallergen sensitization in school age. Individual ORs with 95% CI obtained by logistic regression 
adjusted for sex, parental allergy and parental education. Overall OR with 95% CI derived by random 
effects methods. n=total number of exposed cases, N=total number of included children. 
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3.2.2 Recurrent abdominal pain and IgE-reactivity (IV) 
Aeroallergen sensitization and recurrent abdominal pain 
A subgroup of 2,285 children had available blood samples on IgE-reactivity to common 
airborne allergens (birch, timothy or mugwort pollen, cat, dog or horse dander, mould or 
house dust mites) at four or eight years. The proportions of 12-year-olds sensitized to 
airborne allergens at four and/or eight years were comparable among the 237 children with 
abdominal pain compared to the 2,373 children without abdominal pain, with proportions 
sensitized at four years of 18% and 14% (p=0.17), at eight years 26% and 25% (p=0.78) and 
at both years 32% and 30% (p=0.63), respectively. In logistic regression analyses, 
sensitization to common aeroallergens at ages four and/or eight years was not associated with 
abdominal pain at age 12 years, Table 15.  
Table 15 Associations between sensitization to common airborne and food allergens at age four 
and/or eight years and recurrent abdominal pain at age 12 years among the 2,285 children with 
available blood samples.  
 
Exposure 
OR (95%CI) 
Model I
1
 
OR (95%CI) 
Model II
2
 
Airborne sensitization 4yrs 1.46 (0.96-2.21) 1.17 (0.74-1.83) 
Airborne sensitization 8yrs 1.16 (0.81-1.66) 1.04 (0.71-1.53) 
Airborne sensitization 4 or 8yrs 1.25 (0.89-1.74) 1.04 (0.72-1.49) 
Food sensitization 4yrs 1.87 (1.28-2.74) 1.77 (1.17-2.68) 
Food sensitization 8yrs 1.37 (0.94-1.98) 1.35 (0.91-2.00) 
Food sensitization 4 or 8yrs 1.65 (1.19-2.27) 1.63 (1.15-2.29) 
1
Model I: Logistic regression adjusted for sex.  
2
Model II: In case of positive sensitization we adjusted for sex and the other sensitization. Exposure and 
adjustment variables from the same age of the child. 
Food sensitization and recurrent abdominal pain  
At age four and/or eight years, IgE-reactivity to common food allergens (cow’s milk, egg 
white, soy bean, peanut, cod fish and wheat) were tested in 2,285 children. Food sensitization 
at age four years and at age four or eight years was more common among the 12-year-olds 
with abdominal pain than among those without abdominal pain, with proportions of 23% and 
38% compared to 14% and 27% (p=0.002, p=0.004), respectively. There was a significant 
association between food allergen sensitization at age four years and abdominal pain at age 
12 years after adjustment for sex, OR 1.87 (95% CI 1.28-2.74), Table 15 (model I). The 
significant association remained after having further adjusted for aeroallergen sensitization, 
OR 1.77 (95% CI 1.17-2.68), Table 15 (model II). Similar significant associations were seen 
for food sensitization age four or eight years, with OR 1.65 (95% CI 1.19-2.27) Table 15 
(model I), and OR 1.63 (95% 1.15-2.29) Table 15 (model II). After stratification for parental 
reported food hypersensitivity at the time of positive food sensitization (i.e. at four or eight 
years), a significantly increased risk of recurrent abdominal pain at 12 years was only 
observed among the children whose parents had not reported food hypersensitivity, OR 1.67 
(95% CI 1.06-2.62) compared to children with parental-reported food hypersensitivity, OR 
1.13 (95% CI 0.59-2.17).  
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4 DISCUSSION 
4.1 CHILDHOOD ASTHMA – RISK FACTORS AND CONSEQUENCES 
4.1.1 Wheezing in infancy and school age asthma (I) 
About 25% of all children wheezed at least once during their two first years of life. These 
children had an almost fourfold risk of asthma at age eight years compared to non-wheezers. 
Among the infant wheezers, four independent risk factors were identified for having asthma 
at age eight years. The risk factors were heredity, increased severity of wheeze, infant eczema 
and recurrent abdominal pain. Among wheezing infants with three or four of these risk 
factors, 38% had asthma at age eight years, compared to 7% among wheezers without risk 
factors.  
The observed prevalence of wheeze in infancy is similar to other studies
90, 135, 136
.Wheezing in 
infancy is a known risk factor for asthma development, and the augmented risk observed 
among wheezing children has been shown previously
32, 91, 137
. Moreover, the independent 
associations between heredity, increased severity of wheeze, and comorbidity of eczema and 
school age asthma have been confirmed by others and are well established
31, 87, 138
. However, 
few prospective studies have reported (or assessed) recurrent abdominal pain as a potential 
risk factor for childhood asthma and this finding is discussed in the following section.  
4.1.2 Recurrent abdominal pain and childhood asthma (I, IV) 
In study I, recurrent abdominal pain was reported an independent risk factor for asthma at 
school age in the group of children that wheezed at least once during the two first years of 
life, whereas a significant association between asthma in the two first years of life and 
recurrent abdominal pain at age 12 years was observed in study IV. Asthma at age 12 years 
was also related to an increased risk of concurrent abdominal pain. However, after 
adjustments for other allergy-related diseases under study (allergic rhinitis, eczema and food 
hypersensitivity), asthma did not remain significantly associated with abdominal pain at 12 
years.  
Both study I and study IV indicate an association between asthma and recurrent abdominal 
pain. However, the temporal association between the two conditions remains unclear. 
Questions regarding recurrent abdominal pain were not available in the four and eight year 
the follow-ups, contributing to the difficulties evaluating temporality. In additional analyses 
in this thesis, recurrent abdominal pain remained an independent risk factor for school age 
asthma after restriction of analyses to children that wheezed at least three times in the two 
first years of life (Table 10 and 11, page 35-36). Since the majority of these children satisfied 
the definition of asthma at age two years (Table 9, page 34), recurrent abdominal pain in 
infancy may be a consequence of asthma and not a risk factor for developing asthma as 
suggested in study I. We also performed additional analyses investigating the relation 
between parental reported recurrent abdominal pain during the first two years of life and 
recurrent abdominal pain at age 12 years (page 44). Although there was a significant 
  51 
association between recurrent abdominal pain in the two first years of life and at age 12 years 
(p=0.009), the vast majority (86%) of children with parental reported recurrent abdominal 
pain during the two first years of life did not report recurrent abdominal pain at age 12 years. 
Thus, this additional information is not useful for assessing temporality of recurrent 
abdominal pain. 
Few previous studies have been able to address the temporal relation between recurrent 
abdominal pain and asthma especially in paediatric populations, and the existing results are 
conflicting. Two studies support the conclusion from study I, reporting recurrent abdominal 
pain to precede symptoms of asthma in children. One was a cohort study where a history of 
recurrent abdominal pain was significantly associated with wheeze and asthma up to age 
seven years but not thereafter
113
, the other a case-control study where the majority of 
asthmatics reported symptoms of recurrent abdominal pain having occurred before those of 
asthma
59
. In contrast, a U.K. study following a national sample of children from age seven to 
eleven suggested that wheeze may precede abdominal pain
50
. Two retrospective studies 
reported a significant increase in IBS (irritable bowel syndrome, a specific phenotype of 
abdominal pain
139
) incidence among people who already had asthma
53, 54
, which corresponds 
with the conclusion of study IV. However, clinical symptoms of atopic diseases including 
asthma were not sufficient for IBS occurrence in a selected group of children aged three to 13 
years with severe allergy
79
.  
Regardless temporality, the higher than expected prevalence of concurrent abdominal pain 
observed in 12-year-olds with asthma (study IV) as well as in wheezing infants (study I) 
compared to asymptomatic children is supported by numerous studies
48, 50, 53-62, 76, 77, 140
, 
whereof five include children. This relation emphasizes the potential role of a common 
pathogenetic origin or shared susceptibility to common factors.  
There are several hypotheses regarding mutual mechanistic origins between recurrent 
abdominal pain/IBS and asthma. For example, a generalized abnormality of both bronchial 
and intestinal smooth muscle cells and/or a disturbance of smooth muscle regulation by the 
autonomic nervous system have been suggested, but results are conflicting
58, 78, 141
. This could 
be a plausible explanation to the occurrence of wheeze and recurrent abdominal pain and 
relation to school age asthma in study I. However, no independent association remained 
between asthma and concurrent abdominal pain in the 12-year-olds after adjustment for other 
allergy-related diseases in study IV, indicating that there may be other explanations or that 
this mechanism is not sufficient.  
Conversely, it has been suggested that gastrointestinal side effects related to anti-asthma 
treatment explains the higher prevalence of recurrent abdominal pain/IBS in asthmatics, i.e. 
the association is entirely due to confounding by medication. However, this hypothesis has 
not been confirmed
54, 56, 57
. Constipation and GER (gastroesophageal reflux) are common 
causes of abdominal pain among infants and toddlers
142
, but also among older children 
although to a lesser extent
143
. GER and constipation can be accompanied by wheezing
144, 145
 
and IgE mediated or cell mediated cow’s milk hypersensitivity can trigger these symptoms in 
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infants
146
. Moreover, the prevalence of GER is higher among asthmatic children compared to 
non-asthmatics and can provoke attacks of asthma
147
, and the relation between GER and 
asthma is well recognized
148
. Residual confounding by these abdominal pain-related 
comorbidities cannot be excluded in study I or IV due to lack of information. 
Another hypothesis is that these conditions have a common underlying inflammatory 
process
58
, since the respiratory and gastrointestinal tracts have analogous mucosal-associated 
lymphoid tissue
149
. This inflammation could result in barrier defects in the gastrointestinal 
tract, increasing the risk of disturbed motility and pain sensitivity
67, 80
. Thus, the relation 
between wheeze and recurrent abdominal pain in infancy and asthma in study I as well as the 
significant association between asthma and concurrent abdominal pain at age 12 years could 
be due to a shared low-grade inflammation in the respiratory and gastrointestinal tract. 
Furthermore, one study reported a lower risk of IBS onset among asthma patients with per 
oral corticosteroid medication which has systemic anti-inflammatory effects
53
, although this 
was not confirmed in another study
54
.  
A relationship between inflammation and gut motility or visceral pain perception has been 
proposed
70, 74
. Mast cells are central in allergic inflammation and cause hyperreactive airways 
in allergic asthma. An accumulation of activated mucosal mast cells in the gut have been 
observed in some IBS patients
70, 74
. Mediators secreted by these mast cells may interact with 
sensory nerve endings and promote visceral hyperresponsiveness that lead to symptoms of 
recurrent abdominal pain/IBS
74
. It is therefore plausible that a mutual immunologic 
dysregulation could be part of the explanation of the association between asthma or wheeze 
and recurrent abdominal pain in study I and IV. However, before we can extend the “united 
airways” to the “united mucosa” more mechanistic studies are needed56. 
The question of whether recurrent abdominal pain should be considered a risk factor or a 
consequence of asthma remains to be answered. However, the finding of an increment in risk 
of abdominal pain with increasing number of allergy-related diseases in the 12-year-olds in 
study IV strengthens the hypothesis of a common immune dysregulation, maybe combined 
with a primary neuromuscular disorder producing both respiratory and gastrointestinal 
hyperresponsiveness.  
In additional analyses, recurrent abdominal pain in infant non-wheezers showed elevated 
odds ratios for school age asthma although not statistically significant (Table 12, page 37). 
These results are based on few cases and the hypothesis that symptoms of recurrent 
abdominal pain and infant wheeze originate from abnormal smooth muscle function in the 
bronchi and gut cannot be evaluated. Moreover, food hypersensitivity was an independent 
risk factor in non-wheezers but we cannot exclude that some parents reported this symptom 
due to recurrent abdominal pain. Croup-like cough and cough during activity were 
significantly associated with asthma and bronchial hyperresponsiveness may cause cough. 
Moreover, misclassification of wheezing as croup may explain the association to asthma. The 
significant association between cough and asthma in non-wheezers also serves as a good 
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example of the fact that asthma is more than wheeze. It is not unusual that asthma underlies 
symptoms of prolonged cough or diffuse tiredness in children.  
4.1.3 Maternal smoking during pregnancy and preschool asthma (II) 
We found an association between maternal tobacco smoking during pregnancy and wheeze 
and asthma at four to six years of age in the offspring, even among the in utero exposed 
children that were not exposed to maternal smoking in the first year after birth. Moreover, the 
likelihood of developing wheeze and asthma increased in a dose-dependent manner in 
relation to the daily amount of consumed cigarettes during the first trimester of pregnancy. 
The increased risk for wheeze and asthma in children exposed to maternal tobacco smoke in 
utero has been reported by others
27, 107-109, 111, 116, 150, 151
. In contrast to other studies, our study 
population was sufficiently large to enable assessment of potential independent associations 
between prenatal smoke exposure and wheeze or asthma since 735 (3.4% of the study 
population) children whose mothers smoked only during pregnancy could be identified. 
Furthermore, trimester-specific smoke exposure data allowed for assessment of the risks of 
early but not late foetal smoke exposure. 
Increased risks of wheeze and asthma were present among the 496 children exposed to 
maternal smoking during the first, but not during the third trimester, and not in the first 
postnatal year. However, this early risk was not confirmed in a later study from the 
Generation R birth cohort, where the influence of maternal smoking during the first trimester 
only was insufficient whereas maternal smoking throughout pregnancy significantly 
increased the risk of preschool wheeze
27
.  
Maternal smoking influences the growth and development of the foetal respiratory system 
106, 
152
. For example, nicotine and carbon monoxide in cigarettes reduce blood flow and delivery 
of oxygen and nutrients to the foetus
152
, resulting in impaired overall foetal cell growth and 
development including that of the respiratory system. Lung development commences in the 
fourth week of pregnancy and by the early second trimester the conductive airways down to 
the terminal bronchioles have been formed
153
. This branching morphogenesis is a critical part 
in lung development
153
, and may therefore be a period when the foetus is especially 
susceptible to environmental insults such as tobacco smoke. Thus, the significant association 
between early foetal smoke exposure and preschool wheeze and asthma in our study may be 
explained by timing of exposure with a particularly critical period of lung development. 
Although thousands of compounds are found in tobacco smoke, nicotine seems to be the most 
harmful agent with regard to foetal lung development and maturation
101
. This substance 
passes the placental barrier readily
154
. The developing lung expresses nicotinic acetylcholine 
receptors sensitive to nicotine. This interaction probably underlies many effects of maternal 
smoking on lung development by altering the lung structure in ways that influence lung 
function in the offspring
155
 although the exact mechanisms are still unclear. 
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The observed association between maternal smoking in early pregnancy and wheeze or 
asthma is reinforced by the significant dose-response relation between daily amount of 
smoked cigarettes during the first trimester and preschool wheeze and asthma. It can be 
argued that this relation is explained by continued smoking throughout pregnancy although 
our assessments were restricted to children unexposed to maternal smoking during the first 
year. However, more than two thirds of the mothers that smoked during pregnancy but not 
after delivery succeeded to quit before the third trimester. Furthermore, after exclusion of 
children exposed to maternal smoking during the third trimester from analyses (additional 
results, page 41), the significant dose-response effect remained for asthma, but not for 
wheeze. However, decrements in subgroup sizes increase statistical uncertainty.  
Maternal smoking during pregnancy is an established determinant of foetal growth and risk 
of low birthweight
116
. Birth weight may therefore be considered a mediator of the effect of 
foetal tobacco smoke exposure for childhood asthma. However, when we explored the 
potential mediating effect of birth weight in our analyses, we observed comparable odds 
ratios in models with and without birth weight as an adjustment variable (additional results, 
page 41). This is supported by previous studies reporting none or only a small fraction of 
foetal tobacco smoke exposure effects on asthma development to be mediated through foetal 
growth
27, 116
. In addition, the main influence of tobacco smoke exposure on foetal growth 
occurs during the third trimester
156, 157
. Thus, the association between tobacco smoke 
exposure and respiratory morbidity in the offspring is probably mostly independent of the 
association between tobacco smoke exposure and foetal growth. In hindsight, maybe 
adjusting for birth weight was unnecessary. 
 
We had no information on paternal or other sources of SHS during pregnancy and therefore 
potential associations between maternal SHS exposure during pregnancy and wheeze or 
asthma were not assessed. Although the influence from maternal smoking during pregnancy 
on wheeze and asthma is probably stronger than that of paternal exposure
27, 109
, the lack of 
paternal prenatal smoking data is a limitation. An association between paternal smoking 
during pregnancy and childhood wheeze and asthma has been reported
158
. Therefore, we may 
have underestimated the magnitude of the risk of foetal smoke exposure.  
 
Another potential explanation to our finding of increased risks of early in utero smoke 
exposure on preschool wheeze and asthma may be differences between mothers that quit 
smoking early compared to late in pregnancy with regards to health, lifestyle or other 
uncontrolled factors. If these factors are related to the outcome there may be residual 
confounding. Furthermore, reporting inaccuracies may exist since smoke exposure and 
outcome data were collected through parental questionnaires. For example, pregnant women 
might under report smoking although validation studies have concluded that self-reported 
smoking by pregnant women can be trusted
115, 159, 160
. Non-differential exposure 
misclassification due to under reporting would attenuate the true association.  
 
Mothers who quit smoking early in pregnancy might become more attentive to respiratory 
symptoms in their offspring due to the past smoking history, reporting symptoms and perhaps 
seeking health care more often compared to mothers who continue to smoke. This over 
  55 
reporting would lead to an overestimation of the relative risk for this particular group. On the 
other hand, this could adhere to all mothers that succeeded to quit regardless time point of 
cessation during pregnancy. Contradictory to this theory, a significantly increased risk of 
preschool wheeze and asthma was seen also among the children whose mothers smoked both 
before and after delivery. In addition, under reporting of symptoms and underutilization of 
health care for respiratory symptoms among smoking parents may be even more feasible due 
to the social stigmatization surrounding smoking, particularly in the context of children and 
health
161, 162
. This would result in an underestimation of the true association.  
 
The lack of associations between maternal smoking during the first year after birth and 
preschool wheeze or asthma needs to be addressed. Postnatal tobacco smoke exposure is 
difficult to assess due to its indirect nature compared to direct maternal foetal exposure. 
Parents that report active smoking may avoid exposure of the infant/child due to the known 
health hazards. In addition, the importance of parental smoke exposure decreases with time as 
growing children spend less time at home, which is the commonest source of childhood SHS 
exposure
96
. Disease-related modification of exposure, i.e. parents changing their smoking 
habits when their children show symptoms of respiratory disease ought to be limited due to 
the prospective study design. However, very early respiratory symptoms may to some extent 
increase parental avoidance, contributing to an underestimation of the relative risk of SHS on 
wheeze and asthma.  
 
In contrast to foetal cord blood exposure, the infant is exposed to tobacco smoke via the 
airways. Critical time windows when the airways of the infants are more vulnerable to SHS 
as well as duration of SHS exposure may be important factors for respiratory disease 
development
117
. The induction time in our study may be too short. Other known respiratory 
symptoms besides wheeze such as frequent cough, phlegm and lower respiratory tract 
infections that can be triggered by SHS may influence lung function in a longer perspective. 
What is certain is that infants are vulnerable to SHS since lung structures and the immune 
system continue to develop during the first year after birth and the defence mechanisms are 
still relatively weak
96
. Furthermore, results from a recent systematic review and meta-analysis 
show consistent evidence of a modest association between SHS and childhood asthma
163
.  
 
SHS exposure during infancy is difficult to investigate separately from prenatal exposure 
since these exposures are closely related. Maybe the mothers in our analyses who started 
smoking in the first postnatal year differed in some important way that is related to the 
outcome? One might speculate that they had less asthma or IgE-reactivity, and as a 
consequence these strong predisposing factors for asthma may not have been present in their 
children.  
 
Since pre-and postnatal smoke exposure are closely correlated and affect the incidence of 
wheeze and asthma in the offspring, analysing potential interaction between these two 
exposures may be of value. The additional analyses in this thesis showed no signs of 
significant interaction (additional results, page 41). 
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4.2 CHILDHOOD IgE-REACTIVITY – RISK FACTORS AND CONSEQUENCES 
4.2.1 Recurrent abdominal pain and IgE-reactivity (IV) 
There was an increased risk of abdominal pain at 12 years in children sensitized to food 
allergens at four or eight years. This association remained significant after adjustment for 
sensitization to airborne allergens. Stratified analyses revealed that the augmented risk at 12 
years was confined to children whose parents had not reported food hypersensitivity in their 
children at the time of testing positive to food allergens. Sensitization to airborne allergens at 
four or eight years was not associated with abdominal pain at 12 years. 
Although 20 to 65% of patients with recurrent abdominal pain/IBS self-report induction or 
worsening of gastrointestinal symptoms after ingestion of specific foods
65, 75, 164
, results 
regarding an actual impact of food hypersensitivity on abdominal pain/IBS are 
contradictory
64, 75, 80, 81, 164-167
. However, some studies among adults have suggested a 
causative role of IgE mediated food hypersensitivity in a subgroup of IBS patients that often 
have other signs of atopy
80, 166, 167
. Research regarding food sensitization as a potential risk 
factor for recurrent abdominal pain in children is lacking, but a retrospective study has 
suggested that cow’s milk allergy constitutes a risk factor for the development of functional 
gastrointestinal disorders in children
66
, and a relation between food hypersensitivity and 
intestinal dysmotility has been demonstrated in paediatric populations
145, 168, 169
.  
The finding of a significant association between unrecognized food hypersensitivity in 
children sensitized to common foods and recurrent abdominal pain later in childhood is 
intriguing. It can be speculated that these children continued to ingest foods that they were 
sensitized to, and that this chronic allergen exposure may have contributed to the 
development of recurrent abdominal pain. This corresponds to the previously postulated 
hypothesis that IgE mediated food hypersensitivity plays a causative role for IBS in a 
subgroup of vulnerable subjects
62, 65, 80, 167
. It would have been valuable to have data on 
sensitization to foods among the 12-year-olds. Due to lack of this information, we do not 
know to which extent food sensitization changed over the years and if this change differed 
between the children with and without known food hypersensitivity as well as with or without 
recurrent abdominal pain at age 12 years.  
Another limitation is that the parental-reported food hypersensitivity may not have 
corresponded to the tested food items at age four and eight years, thus we cannot be sure that 
these children actually avoided the foods they were sensitized to. In addition, sensitization 
does not equal clinical allergy and although the cut-off of >0.35 kUA/l is commonly used 
when assessing sensitization, a positive as well as negative test result does not equal presence 
and absence of clinical IgE mediated allergy, i.e. symptoms may occur below the threshold 
value and clinical tolerance may be present although still testing positive. In post hoc 
analyses, a variable of food allergy was created combining reported food hypersensitivity and 
concomitant positive food sensitization with a doctor’s diagnosis of food allergy between one 
and 12 years. Children with food allergy at age four or eight years had significantly more 
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abdominal pain at age 12 years. It is therefore reasonable to believe that an association 
between IgE mediated food hypersensitivity, food sensitization and food hypersensitivity and 
recurrent abdominal pain exists in children. However, the question regarding causality 
remains unanswered since we cannot rule out that recurrent abdominal pain existed before the 
age of 12 years.  
The association between positive sensitization/food hypersensitivity and recurrent abdominal 
pain is biologically plausible. Mediators of activated mast cells are known key players in 
allergic inflammation. Mast cells are found in increased numbers through the gut mucosa of 
IBS patients
62, 74
, and mediators such as tryptase contribute to visceral hyperalgesia
62, 73
. The 
severity of pain perception in IBS patients has been directly correlated to the close proximity 
between nerve fibres and mast cells
74
. Mast cells also interact with epithelial cells, enhancing 
permeability of the epithelial barrier as well as mucosal inflammation
62, 70
. Mucosal mast 
cells can be activated by a number of stimuli including allergens and can thereby be linked to 
both allergy and IBS
62
. Tobin et al observed that patients with an allergic background had 
more severe gastrointestinal symptoms, a higher number of mucosal mast cells and high 
intestinal tryptase release
62
. In conclusion, mast cell activation can be involved in both allergy 
and IBS, with additive or synergistic effects on symptoms of abdominal pain 
62
.  
On the other hand, the barrier defects seen in IBS patients may enhance entry of allergens 
through the mucosa and promote sensitization with subsequent occurrence of adverse 
reactions and not the other way around. In an intact mucosal barrier only small quantities of 
antigen or pathogens cross beyond the epithelium
165
. This could for example be one 
explanation to the high incidence of food allergy in young children whose mucosal barrier is 
immature. Whether allergy or sensitization is a risk factor or consequence of barrier defects 
and/or inflammation in IBS thus remains to be determined.  
Airborne allergens are probably also partly ingested with the possibility to bind and activate 
mast cells in the gut
170
. We saw no association between airborne sensitization and recurrent 
abdominal pain, and adjustment for airborne sensitization did not influence the association 
between food sensitization and recurrent abdominal pain. The lack of association in our study 
indicates that in children aged eight to 12 years, pollen allergen cross-reactivity with food 
may not be an important trigger of abdominal pain. However, the incidence of sensitization to 
airborne allergens and clinical symptoms of cross-reactive allergy such as the oral allergy 
syndrome has not reached its peak at this age and may be a more important factor later in life 
although an association was not confirmed in an adult study
167
.  
One potential methodological weakness in our study may be the use of serum IgE antibody 
data only. Serum IgE antibodies or SPT may not be optimal methods for assessing food 
sensitization in subjects with food hypersensitivity dominated by gastrointestinal symptoms. 
It has been suggested that provocation tests directly on the colon mucosa may be a more 
sensitive method
171
. 
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4.2.2 Tobacco smoke exposure in infancy and IgE-reactivity (III) 
There were no apparent associations between tobacco smoke exposure during pregnancy or 
infancy and aeroallergen sensitization later in childhood, except between SHS exposure in 
infancy and pet sensitization in preschool age, where a tendency towards an increased risk 
including a significant dose-response effect was observed. 
Our results showing no associations between early SHS exposure and aeroallergen 
sensitization during childhood corresponds with previous studies that assessed aeroallergen 
sensitization separately from food allergens
127, 129, 130, 172
. However, when aeroallergen 
subcategories were analysed, there was a significant association between any SHS exposure 
in infancy and pet sensitization in preschool age including a significant-dose response effect. 
There are plausible biological explanations to this association. Pet allergens reach the airway 
mucosa with ease due to their more volatile nature compared to house dust mite allergens. 
Two potential mechanisms of how SHS could promote aeroallergen sensitization have been 
suggested. SHS may interact directly with the allergen and promote the allergenic capacity
122, 
123, 173, 174
. SHS also have direct irritant effects on the airway mucosa, causing inflammation
120
 
that may facilitate the penetration of aeroallergens and increase the risk of sensitization. 
Hypothetically, air pollution from other sources than SHS could augment the risk of 
aeroallergen sensitization by similar irritant effects. However, this was not confirmed in a 
recent pooled analysis assessing the association between traffic-related air pollution and 
sensitization where several of the cohorts from this study were included
175
. 
A recent meta-analysis of published studies concluded that a moderately increased risk of 
food or aeroallergen sensitization was present among children exposed to household tobacco 
smoking, and that this risk was confined foremost to preschoolers. The associations were 
stronger in cohort studies compared to case-control studies
28
. However, we found no previous 
studies supporting the finding of an association between SHS in infancy and preschool pet 
sensitization. Lannerö et al. have previously observed this association in the BAMSE cohort
29
 
but this agreement of results may be explained by the substantial contribution to the pooled 
estimate by BAMSE in our analyses. Another possible explanation that deserves mentioning 
is the problem that arises with multiple comparisons. Since many statistical comparisons 
were made in this study, the risk of falsely rejecting a true null hypothesis may be an 
explanation to this isolated finding. 
Some studies have reported interactions between SHS exposure and inherited predisposition 
for allergy, but the observations are conflicting. Augmented risks have been found in children 
with
110, 127
 as well as without
128
 an allergic predisposition. We found no evidence of effect 
modification by parental allergy on SHS exposure. The discrepant results may have several 
explanations. For example, differences in avoidance behaviour may exist between the allergic 
and non-allergic parents and symptoms of atopy such as infantile eczema may be recognized 
earlier by allergic smoking parents, possibly leading to a disease-related modification of 
exposure in this group. In addition, the definitions of exposures and allergic heredity are 
heterogeneous with varying numbers and types of parental allergies included in the 
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definitions of allergic heredity across studies. Moreover, immune responses to SHS may 
differ with regard to sensitization status. Murine models have shown immunosuppressive 
effects in already sensitized mice
121, 123, 176
 whereas primary sensitization has been 
demonstrated in mice without prior sensitization
122, 173, 174
.  
In contrast to study II, we were not able to study independent associations of prenatal and 
postnatal tobacco smoke exposure due to lack of sufficient statistical power in study III. 
Adjustments for pre- and postnatal tobacco smoke exposures in the respective regression 
models did not reveal any independent associations. Nevertheless, the impact of tobacco 
smoke on the foetal immune system may differ from that of postnatal exposure due to 
differences in immune maturation as well as routes of exposure.  
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4.3 STRENGTHS AND LIMITATIONS 
The major strength of this thesis is that all studies were based on data from birth cohorts with 
prospective designs where exposures were assessed before disease onset. The exposure and 
disease assessments were detailed and follow-ups were conducted at several occasions. The 
cohorts were based on population-based samples, rendering results that apply to the general 
paediatric population. 
Study I and IV were based on data from the BAMSE birth cohort. This cohort contains a 
comparatively large unselected group of children enabling analyses of subgroups and 
allowing for stratification. The high initial participation rate and limited loss to follow-up 
reduce selection bias and increase generalizability of results.  
Study II and III comprised of data from eight European birth cohorts from the ENRIECO 
project. All cohorts were initially designed to study the development of asthma and allergies 
in childhood and individual participant data were harmonized before the analysis stage which 
reduces between-study heterogeneity. The pooling process created a large study population 
with high statistical power and allowed for assessment of associations between tobacco 
smoke exposure and asthma or IgE-reactivity in various populations. Furthermore, the large 
study size in study II enabled us to study separate risks of pre- and postnatal smoke exposure 
on the development of wheeze and asthma, and also to perform sensitivity analyses by 
restriction and exclusion of groups with characteristics that may have confounded 
associations.  
One weakness is that all exposures and outcomes were based on questionnaire data except for 
IgE-reactivity. Other potential weaknesses that have to be considered in observational studies 
are discussed in the following section. 
 
4.4 METHODOLOGICAL CONSIDERATIONS 
Epidemiological studies may be afflicted by errors that affect precision, validity and 
generalizability of the results. The two main categories consist of random error and 
systematic error
177
. 
4.4.1 Random error 
Random errors are the result of unexplained variability in the data and occur in all 
observational studies with finite study populations. This variability is reflected by the width 
of the confidence intervals and can be reduced foremost by increasing the size of the study 
population. Confidence intervals were computed for all associations in the studies of this 
thesis in order to provide accurate information about the precision of the investigations.  
Study I and IV consisted of 3,251 and 2,610 children and the confidence intervals in the main 
analyses were rather narrow, reflecting good precision. The main focus in study I was on 
disease development in the subgroup of 823 infant wheezers and although the initial 
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population sample was large, some subgroup sizes became small rendering statistical 
uncertainty. In recent years, research collaborations such as ENRIECO have become 
frequent, and the very large study populations render markedly increased precision. Study II 
and III included individual participant data from eight cohorts and consisted of 21,600 and 
14,613 children, respectively. 
4.4.2 Systematic error 
Systematic errors (or bias), do not depend on study size or chance. These errors may occur at 
all stages in the research process, resulting in reduced validity of the observed results. The 
most common types of bias are addressed here. 
4.4.2.1 Selection bias 
Selection bias stems from the procedures used to select subjects and from factors that 
influence study participation
177
. It occurs when nonparticipants and/or subjects lost to follow-
up differ from those remaining in the study in ways that affect the association between the 
studied exposure and disease. Selection bias at recruitment influences the extent to which the 
findings can be generalized to populations outside the study population.  
The BAMSE cohort included 75% of all eligible children. The associations between exposure 
and disease are usually unknown among the nonparticipants and the presence of selection 
bias must be inferred. In the BAMSE cohort a survey was sent out to the excluded and the 
non-responders and the answers revealed no significant differences regarding characteristics 
such as allergic heredity or pet ownership. However, parental tobacco smoking was more 
prevalent in this group
131
. 
In ENRIECO, the proportion of recruited children ranged from around 55% to 95% of the 
target populations and some cohorts have provided information on the nonparticipants. For 
example, ALSPAC observed an underrepresentation of characteristics associated with lower 
socioeconomic status among the included children
178
. Nonparticipants were similar with 
regard to maternal age, birth weight and gestational age in DARC
179
. GINIplus reported no 
differences regarding socio-economy or allergic heredity between nonparticipants/very early 
drop-outs and the study population
180
.  
Loss to follow-up is another source of selection bias. The response rates have remained 
comparatively high in the BAMSE cohort throughout the years, with 82% of the original 
cohort still participating at 12 years of age and selection regarding important characteristics 
has remained low
47
. The children that provided blood samples do not differ significantly from 
the original BAMSE cohort regarding important background characteristics such as sex and 
parental allergy. 
Response rates in the other ENRIECO cohorts at age six to eight years range from 49% 
(ALSPAC) to 95% (AMICS-Menorca) of the original study populations, with mean response 
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rate around 86%. Overall, no selection of greater importance has been reported although non-
smoking parents with a higher education remain in the studies to a greater extent.  
The inclusion criteria in the separate studies may also introduce selection bias due to 
differences between included and excluded children with regard to background characteristics 
or symptoms. In study I and IV there were no significant differences except for a slightly 
higher socioeconomic status among the included children. Furthermore, parents to children 
included in study II and III had a higher educational level and smoked less. The children 
included in study III were breast fed longer and their parents were more allergic. If these 
biases are related to the outcomes in any of the studies in this thesis they may have attenuated 
the observed differences. 
4.4.2.2 Information bias 
The collected information about or from study subjects may be erroneous, resulting in 
misclassification of exposure or disease. This misclassification can be differential or non-
differential, referring to the mechanism of misclassification. Misclassification of exposure is 
non-differential if unrelated to the occurrence or presence of disease and differential if the 
exposure is different for those with and without disease. In the same way, misclassification of 
disease is non-differential if unrelated to exposure, otherwise it is differential
177
. All 
information in the studies regarding exposures and allergy-related symptoms was based on 
parental questionnaires, except for the questions regarding recurrent abdominal pain that were 
answered by the 12-year-olds themselves in study IV.  
Misclassification of exposure is probably non-differential in most cases due to the 
prospective study designs, although later exposures may be have been modified by early 
disease onset. For all allergy-related diseases there is probably some non-differential 
misclassification due to the delicate balance between sensitivity and specificity, i.e. missing 
cases with too strict outcome definitions or classifying non-cases as allergic with more 
inclusive definitions.  
The wheeze definition was in accordance with the ISAAC (International study of asthma and 
allergies in childhood) study criteria
8
 in study I. The definitions of wheeze varied somewhat 
across cohorts included in study II, but all contained similar descriptions of the characteristic 
respiratory symptoms known as wheeze occurring in the last 12 months.  
Asthma is difficult to measure in epidemiological studies because there are no definitive 
diagnostic criteria or universal gold standard
181
. Furthermore, it is a dynamic disease with 
alternating periods of exacerbations and quiescence of symptoms. In study I and IV we used a 
definition combining wheeze symptoms and asthma medication in the last 12 months since 
we wanted to predict chronic disease with clinical relevance. Asthma medication can be 
considered a proxy for a physician-diagnosis of asthma (which is sometimes considered the 
gold standard) since it is issued if the child has been diagnosed with asthma after evaluation 
by a physician. Combining medication with current symptoms ensures that the child is 
currently suffering from the disease and has not outgrown symptoms, which is common 
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before school age. In study II, two of three criteria had to be fulfilled out of the following; 
current wheezing symptoms, current asthma medication or a doctor’s diagnosis of asthma 
ever. This definition has the same advantage as the one used in study I and IV, considering 
the fact that asthma is a dynamic disease by capturing current cases. 
The definition of eczema used in study I and IV has been validated in the BAMSE children 
up to age two years and the results showed a 92% sensitivity and 100% specificity compared 
to a diagnosis of eczema after clinical examination by a dermatologist
182
. A similar definition 
was used at later ages and although not validated, the characteristic symptoms and 
localization of eczematous lesions should be easier to recognize in older children.  
Allergic rhinitis in study IV was defined based on symptoms from eyes and/or nose at pollen 
or pet exposure with or without a doctor’s diagnosis of allergic rhinitis. A Finnish validation 
study concluded that diagnosis-based questions regarding allergy were suitable for risk-factor 
studies due to good specificity and high positive predictive value, and symptom-based 
questions were adequate when screening for disease because they were highest in 
sensitivity
183
. The combination of symptoms and physician diagnosis should therefore have 
good sensitivity and specificity. Since symptoms at allergen contact was required the risk of 
falsely classifying symptoms of common colds as allergic rhinitis decreased. 
The definitions of asthma, eczema and allergic rhinitis have been used in previous peer-
reviewed studies
47, 184, 185
. 
Food hypersensitivity was assessed in study I and IV. The gold standard for verifying 
suspected food hypersensitivity is by food challenges. This has not been done in all BAMSE 
children with suspected food reactions since it is time consuming and costly. The prevalence 
of subjective food hypersensitivity in young children has been reported to be up to 35% of 
which only a few percent are verified in food challenges
186
 and the majority of food 
sensitized children do not have any corresponding symptoms
187
. Moreover, to ask parents and 
children to perform food challenges could cause anxiety and jeopardize future participation in 
the study. In post hoc analyses in study IV, a variable for food allergy was created where 
suspected symptoms of food hypersensitivity, a physician diagnosis and positive food 
sensitization were combined. This variable probably had a higher sensitivity compared to the 
food hypersensitivity definition with regard to IgE mediated food allergy.  
Recurrent abdominal pain in study I was defined solely as presence or absence and this 
definition has not been validated. Knowledge about intensity, frequency and symptoms 
associated to abdominal pain in infants and toddlers such as GER or constipation would have 
been of benefit. The smaller the infant the more difficult it is for parents to disentangle 
symptoms from the gut from other reasons of discomfort. It cannot be excluded that other 
factors associated with school-age asthma such as early wheeze-like respiratory morbidity 
may have confounded the association.  
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In contrast to the other outcomes that were based on parental reports, recurrent abdominal 
pain in 12-year-olds had the advantage of being self-reported. The definition was not entirely 
in accordance with the paediatric ROME III
139
 or Apley criteria
188
, but similar prevalence’s 
of abdominal pain observed in study IV have been obtained in studies using the established 
definitions. The BAMSE cohort involves researchers from various research areas with 
different interests. What to include in each follow-up must be considered carefully. Lengthy 
questionnaires or embarrassing questions for 12-year-olds to answer (for example on stool 
characteristics) may reduce response rates. Questions regarding gastrointestinal symptoms 
were left out from the shortened questionnaire that was used in telephone interviews or 
mailed to families that had not answered the web based questionnaire. 
Misclassification may have occurred regarding recurrent abdominal pain in study I since 
some parents may be more attentive to adverse symptoms in their children, over reporting 
wheeze as well as recurrent abdominal pain in their infants. This would make the relation 
between these symptoms appear stronger than it is. However, over reporting of symptoms 
would probably be unrelated to the outcome, having no influence on the estimated association 
to school age asthma unless these parents share some other characteristic that is associated 
with the outcome. One such factor could be parental allergy, but we did adjust for this. In the 
same way, children with allergic diseases may report more symptoms in general, resulting in 
stronger associations between recurrent abdominal pain and asthma or other allergy-related 
diseases at age 12 years in study IV.  
The tests used for detecting IgE-reactivity to aeroallergens (study III, IV) and foods (study 
I, IV) have shown good correlation to SPT and IgE antibodies measured by the CAP-RAST 
test
189
. Although the cut-off value of 0.35 kUA/l is widely used, positive and negative 
values do not equal presence or absence of clinical symptoms. However, the aim in study 
III was to assess the modulating effect of SHS on foetal and infant immune systems and in 
study IV to investigate if immune dysregulation causing allergy/sensitization also has a role 
in the development of recurrent abdominal pain and in this respect the cut-off can be 
considered purposeful. Moreover, it enables comparison of results with previous existing 
studies.  
Information on parental tobacco smoking, the main exposure in study II and III, was based 
on parental self-reports and the lack of objective measures is a limitation. Under reporting 
of smoking may be present do to the social stigma associated with smoking as well as 
parental awareness of potential health hazards related to in utero and postnatal smoke 
exposure. After delivery, avoidance behaviour may significantly reduce direct exposure of 
the child although parents report active smoking. Moreover, parents may not smoke the 
same amount every day and the avoidance patterns may vary at different time points. This 
misclassification of exposure would be non-differential. However, if smoking parents 
modify the exposure due to very early symptoms in the child or if these parents report 
smoke exposure differently than parents of healthy children, the magnitude of the 
association will appear weaker than it is.  
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Although parental smoking at home is the main source of SHS exposure in children, 
significant exposure to SHS in other environments may be present and we have probably 
underestimated the true prevalence of smoke exposure. This also applies to the reference 
group. Although this group consisted of mothers or fathers reporting not to smoke, the 
concentration of metabolites of nicotine in urine and hair in children from smoke-free 
homes indicate that they also are exposed to SHS to some extent and therefore are not truly 
unexposed
112
.  
4.4.2.3 Confounding 
Confounding occurs when other factors than the studied affect the relation between exposure 
and outcome, making associations seem stronger or weaker than they are. Confounding can 
be controlled for if accurate information is available about these factors. However, influence 
of unknown or unmeasured factors (residual confounding) can never be entirely excluded. 
Multivariate regression models were used in all studies which enabled for adjustment for 
several confounders. 
We lacked information on certain important factors related to abdominal pain in infancy thus 
residual confounding may exist in study I. The same concerns the relation between allergy-
related diseases and recurrent abdominal pain in study IV. Some factors differ between 
infants (study I) and 12-year-olds (study IV) due to differences in maturity and age dependent 
comorbidities to abdominal pain. For example, infantile colic has been identified as an early 
life factor for frequent wheezing and asthma
190
. Infantile colic is often perceived as attacks of 
abdominal pain by parents. However, since this condition remits around age three months and 
infants below six months were not included in the definition of recurrent abdominal pain, 
confounding by infantile colic is less probable in study I. Furthermore, we had no information 
on common abdominal pain-related comorbidities such as constipation and GER in study I 
and IV, thus residual confounding may exist. 
Food hypersensitivity is another potential confounder to recurrent abdominal pain in study I. 
Food hypersensitivity is common in infancy, with the majority remitting before the age of 
three years
44
. Food hypersensitivity, particularly symptoms at ingestion of cow’s milk and 
wheat were related to recurrent abdominal pain in study I. However, food hypersensitivity did 
not completely explain the association between recurrent abdominal pain in the wheezers and 
school age asthma. Food hypersensitivity at age eight and 12 years and food allergy at four or 
eight years were significantly associated with recurrent abdominal pain at age 12 years in 
study IV. This could imply that recurrent abdominal pain in the infant wheezers also can be 
due to food allergy. Unfortunately, data on IgE antibodies to common food allergens were not 
available from the first two years of life making this impossible to evaluate. Recurrent 
abdominal pain in infancy was not significantly associated with elevated IgE levels to food 
allergens at age four years (p=0.89). However, IgE mediated food hypersensitivity is more 
often accompanied by wheeze in contrast to cell mediated hypersensitivity and lack of IgE 
data in infancy is a limitation in study I
44
.  
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We did not adjust for heredity of recurrent abdominal pain although IBS has a strong familial 
trend, with the association being the strongest if one parent has IBS
191
. Although heredity 
contributes to IBS, social learning has an equal or greater influence
191
 and this factor is 
difficult to account for in epidemiological studies.  
In study IV many potential confounders were tested but only sex led to a more than 10% 
change in OR. Adjustments were made for all allergy-related diseases besides the one under 
study, taking into account the frequent coexistence of allergic symptoms.  
Mental stress is a potential confounder in study IV. Children with multiple allergy-like 
diseases may experience stress due to their physical health status and this stress may 
contribute more than immune dysregulation to recurrent abdominal pain. The observed 
“dose-response” pattern of allergy burden on recurrent abdominal pain could in this case be 
explained by an increment in stress with increasing allergy burden. It can also be speculated 
that parents to wheezing infants experience more stress and that these emotions cause 
discomfort in the infant that is interpreted as recurrent abdominal pain in study I.  
Tobacco smoke exposure, an established risk factor for infant wheeze and asthma
114
, was 
associated with recurrent abdominal pain (p=0.018) in study I but not in study IV. However, 
the significant association remained between recurrent abdominal pain in wheezers and 
school age asthma after adjustment for maternal tobacco smoke exposure in study I.  
In study I and II with childhood asthma as outcome, adjustments were made for known or 
suspected risk factors for respiratory allergy and factors that influenced the estimates. Study 
II and III included eight cohorts that all provided information derived from different 
questionnaires. All cohorts had collected similar information on the most important known 
confounders of asthma and atopy. However, heterogeneity across cohorts was quite large 
regarding questions concerning breast feeding. This may mirror the existing differences in 
policies regarding economic support and duration of parental leaves between countries. For 
example, Swedish children were exclusively breast fed longer which may be due to generous 
economic support and comparatively long parental leaves.  
An important source of bias when evaluating the associations between tobacco smoke 
exposure and different health outcomes is socioeconomic status. This can be defined in many 
ways for example as parental occupation, mother’s age at delivery, household income, 
residential characteristics etc. Although educational systems vary between countries they 
correlate well to years of schooling. Therefore the numbers of educational years were 
harmonized across studies into three categories referring to high, middle or low parental 
educational level, counting the parent with the highest educational level as representative for 
the socioeconomic status of the family in study II and III.  
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4.4.3 Generalizability 
Generalizability can be viewed as the extent to which results from epidemiologic studies can 
be inferred to populations outside the one actually studied
177
. It can be assumed that the 
observed associations of this thesis are generalizable to European (study II and III) and 
Swedish (study I and IV) children from urban and suburban environments. Due to some 
degree of selection regarding socio-economy and parental smoking, the role of SHS exposure 
in the general paediatric population may be underestimated. The proportion of included 
children with and without allergic predisposition was determined in the study design in MAS 
and for a subgroup of participants in PIAMA-NHS, and the observed prevalence of parental 
allergy may not reflect that of the general paediatric population in the respective catchment 
areas
192, 193
.  
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4.5 CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES 
The results from study I consolidate previous knowledge regarding early factors associated 
with childhood asthma development, namely infant wheeze, increased severity of wheeze 
symptoms, concomitant eczema and allergic heredity. A risk factor that has not been reported 
extensively in this context is recurrent abdominal pain. Although residual confounding may 
have been present in the study, recurrent abdominal pain as perceived by the parents in their 
wheezing infants was associated with asthma at school age. Asking about recurrent 
abdominal pain is easy in the clinical setting and may be of prognostic value, although further 
studies are needed to confirm the association. Future research from prospective studies may 
reveal whether early gastrointestinal symptoms such as abdominal pain in wheezing infants 
reflect a lifelong tendency for abnormal function at both the gastrointestinal and bronchial 
mucosal surfaces or not.  
An association between allergy-related symptoms and recurrent abdominal pain at age 12 
years was observed in study IV, especially with regard to eczema and food 
allergy/hypersensitivity. Based on these results, clinicians should have a low threshold for 
considering potential allergy as contributing to symptoms of recurrent abdominal pain in their 
paediatric patients. Therapeutic options may differ between atopic and non-atopic children 
with abdominal pain. However, which these might be remains to be determined.  
The observed association between allergy-related diseases and recurrent abdominal pain in 
study I and IV further reinforces the need of future prospective studies focusing on asthma 
and allergies to include questions on gastrointestinal symptoms and use established 
definitions of paediatric abdominal pain. Gathering of information regarding confounding 
factors and detailed follow-ups for evaluation of disease temporality and potential causal 
effects is merited. 
Due to the intriguing finding of an association between food sensitization in four or eight year 
old children without reported food hypersensitivity and recurrent abdominal pain at age 12 
years, a future research implement in BAMSE would be to investigate if these children differ 
regarding food sensitization, food hypersensitivity and recurrent abdominal pain at 16 years 
of age compared to the food sensitized children with known food hypersensitivity at age four 
or eight years. This is possible due to available data on sensitization and abdominal pain in 
the 16-year follow-up. The results may or may not strengthen the hypothesis that chronic 
mucosal inflammation can cause symptoms of both allergy and recurrent abdominal pain and 
that undetected food sensitization may precede symptoms of abdominal pain. More 
mechanistic studies of the gastrointestinal tract of allergic versus non-allergic subjects are 
also needed in order to increase knowledge on how specific immune reactions related to 
allergy may involve the gut and in particular in which ways the intestinal mucosa is affected.   
A significant association was seen between prenatal exposure and preschool wheeze or 
asthma in study II, even in children whose mothers quit smoking early in pregnancy. This 
information can be used by health care professionals in order to motivate women not to start 
smoking or to quit before conceiving to prevent asthma in their children.  
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Although an independent association between early prenatal smoke exposure and 
development of preschool wheeze and asthma was observed in study II, no clear associations 
were seen between pre- or postnatal tobacco smoke exposure and aeroallergen sensitization in 
study III. It would be interesting to investigate if in utero smoke exposure foremost increases 
the risk of a particular phenotype of asthma. The non-atopic asthma phenotype usually has a 
better prognosis compared to atopic asthma. Further assessments of the same outcomes 
beyond preschool age could provide valuable information on long-term prognosis. 
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5 CONCLUSIONS 
Based on the results from the studies, in utero tobacco smoke exposure, allergic heredity and 
comorbidity as well as increased severity of symptoms in infant wheezers are associated with 
an increased risk of childhood asthma. Furthermore, allergy-related diseases and food 
sensitization are associated with recurrent abdominal pain at age 12 years. On the contrary, 
no convincing associations exist between early life tobacco smoke exposure and aeroallergen 
IgE-reactivity or between aeroallergen IgE-reactivity and abdominal pain at age 12 years. 
The separate studies in this thesis suggest the following conclusions: 
 The risk of having asthma at age eight years is almost fourfold among the group of 
children that wheezed at least once during the two first years of life compared to the 
non-wheezers. Risk factors independently associated with school age asthma in these 
infant wheezers were: increased severity of wheeze, infant eczema, recurrent 
abdominal pain and allergic heredity. Recurrent abdominal pain as a risk factor has 
been sparsely reported before and residual confounding may be present. 
 
 Maternal tobacco smoking during pregnancy is associated with an increased risk of 
wheeze or asthma in the offspring at preschool age. An augmented risk is present 
even among children that are not exposed late in pregnancy or after birth. This 
information is important when motivating young women to stop smoking before 
getting pregnant to prevent asthma in their children. 
 
 There are no apparent associations between maternal tobacco smoking during 
pregnancy or SHS exposure in infancy and sensitization to pets, house dust mite, 
pollen or all aeroallergens combined in preschool or school age. 
 
  An association between SHS exposure in early infancy and pet sensitization in 
preschool age including a significant dose-response effect was observed but this 
isolated finding needs to be replicated.   
 
 Allergy-related diseases at the age of 12 years are associated recurrent abdominal pain 
at the same age. Food sensitization and food allergy at age four or eight years is 
associated with recurrent abdominal pain at 12 years. Although causal relationships 
cannot be determined in this study, the results support the hypothesis that allergic 
disease and recurrent abdominal pain have common immunologic pathways.  
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6 SAMMANFATTNING PÅ FINLANDSSVENSKA 
Bakgrund 
Antalet barn som insjuknar i allergisjukdomar har ökat under de senaste decennierna, 
speciellt i länder där den industriella utvecklingen nått långt. Samtidigt har nivåerna av 
mätbara IgE-antikroppar mot allergiframkallande ämnen också ökat. Idag har upp till vart 
tredje barn eller ungdom i Europa någon form av allergisjukdom och astma är den vanligaste 
kroniska barnsjukdomen i västvärlden. Under senare år har man kunnat skönja en avplaning 
avseende antalet nyinsjuknanden i astma i vissa länder.  
Anledningen till den ökade förekomsten av allergisjudomar är multifaktoriell och komplex, 
bestående av ett samspel mellan arv och miljö. Även tidpunkten för exponering för olika 
miljöfaktorer spelar stor roll och extra känsliga stadier förefaller vara fosterlivet och 
nyföddhetsperioden.  
Det finns ett tidssamband mellan ökad allergiförekomst och en förändrad livsstil med högre 
levnadsstandard, ökad renlighet, förändrad kost och bättre sjukvård. En hypotes är att vi 
exponeras för mindre infektioner och bakterier tidigt i livet och att detta leder till att vårt 
immunförsvar tenderar att reagera på ett allergiskt sätt om en underliggande sårbarhet finns. 
Därtill har astmaförekomsten ökat i takt med den urbanisering som medfört en ökad utsatthet 
för miljöföroreningar såsom tobaksrök och trafikavgaser. Ett samband har påvisats mellan 
mammans rökning under graviditeten och astma hos barnet, men det har varit svårt att helt 
särskilja effekterna av rökning under och efter graviditeten då många mammor fortsätter röka 
efter att barnet fötts. Säkra samband har inte kunnat styrkas vad gäller tobaksröksexponering 
tidigt i livet och förekomst av IgE-allergiantikroppar hos barnet. 
Allergiska symptom följer ofta ett typiskt mönster i barndomen. Under de första 
levnadsmånaderna debuterar ofta eksem och vissa spädbarn blir (oftast övergående) 
allergiska mot mjölk- eller äggprotein. Under andra halvan av första levnadsåret kan 
astmaliknande pipande och väsande andningsbesvär debutera men endast en minoritet av 
dessa barn utvecklar astma. Hösnuva och astma blir successivt mer vanligt i skolåldern och 
tonåren samtidigt med en ökad förekomst av pollen- och pälsdjursallergier. Många försök har 
gjorts för att identifiera de barn med tidiga astmaliknande symptom som löper en högre risk 
att utveckla astma men hittills finns ingen metod som är av kliniskt värde.  
Det finns studier som tyder på att allergi kan ge upphov till symptom från andra organ än de 
som vi vanligen förknippar med sjukdomen. Huvudvärk, migrän, muskelvärk och 
återkommande buksmärta har visat sig vara vanligare hos allergiska än icke-allergiska 
individer i vissa studier. En teori är att allergisk inflammation som uppstår i ett organ kan 
spridas till andra vävnader som har ett gemensamt immunologiskt ursprung, till exempel 
mellan luftvägarnas och tarmens slemhinnor. Tidigare studier avseende sambandet mellan 
allergiska symptom och buksmärtor har oftast varit små och de flesta har haft vuxna 
studiepopulationer. Därtill har resultaten inte varit entydiga. 
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Syfte 
Syftet med denna avhandling var att: 
Studie I. Undersöka vilka egenskaper och symptom hos barn med tidiga andningsbesvär som 
ökade risken för ha astma i åttaårsåldern. 
Studie II. Studera sambandet mellan mammans rökning under graviditeten och astma hos 
barnet i fyra- till sexårsåldern. 
Studie III. Undersöka sambandet mellan exponering för tobaksrök i fosterlivet eller 
nyföddhetsperioden och förekomst av allergiantikroppar mot pälsdjur, dammkvalster eller 
pollen hos barnet i förskole- och tidig skolålder. 
Studie IV. Studera om det finns ett samband mellan allergiska symptom eller förekomst av 
allergiantikroppar under uppväxten och återkommande buksmärta hos barnen vid 12 års 
ålder. 
Metod 
Studie I och IV baseras på data från BAMSE-projektet (Barn, Allergi, Miljö, Stockholm, 
Epidemiologi) där 4,089 barn födda mellan 1994 och 1996 följts regelbundet med enkäter 
och blodprovstagning från cirka två månaders ålder. I studie I användes information från 
föräldraenkäter då barnen var ett, två och åtta år och blodprovstagning vid fyra år. I studie IV 
användes information från föräldraenkäter vid ett, två, fyra, åtta och 12 år samt data från 
blodprovstagning vid fyra och åtta år. Barnen själva svarade på enkätfrågor om buksmärta vid 
12 år. I studie I kunde 3,251 barn inkluderas och i studie IV var antalet barn 2,610. 
Studie II och III baseras på data från åtta europeiska studier (totalt 32,774 barn) varav en var 
BAMSE. Alla barn hade följts från födelsen och alla kohorter startades på 90-talet. I studie II 
kunde 21,600 barn inkluderas i analyserna och i studie III 14,613 barn. Adekvat information 
om rökning under graviditeten och första levnadsåret var ett krav i båda studierna samt 
tillgänglig information om andningsbesvär och astma mellan fyra och sex år (studie II) och 
allergiantikroppar mellan tre och fyra år eller sex, sju eller åtta år (studie III). 
Resultat (ett urval) 
En fjärdedel av BAMSE-barnen hade tidiga astmaliknande andningsbesvär, och av dessa 
barn hade 14 procent astma vid åtta års ålder. I gruppen barn utan andningsbesvär hade 
knappt fyra procent utvecklat astma vid samma ålder. Faktorer hos barnen med tidiga 
andningsbesvär såsom ärftlighet för astma eller allergi, mer uttalade andningsbesvär (mer än 
tre episoder med andningsbesvär, behandling med inhalationskortison eller besvär både första 
och andra levnadsåret), samtidigt eksem och återkommande buksmärta medförde en 
signifikant ökad risk för astma vid åtta år. 
Cirka nio procent av 12-åringarna uppgav att de hade återkommande buksmärta minst varje 
månad och då var menstruationssmärta inte medräknad. Ett signifikant samband kunde 
påvisas mellan samtliga allergirelaterade symptom vid samma ålder och återkommande 
buksmärta vid 12 år. Dessutom ökade sannolikheten för återkommande buksmärta med 
ökande antal samtidigt förekommande allergiska symptom. Ett samband mellan tidig astma 
(ett och två år) och återkommande buksmärta vid 12 år observerades också. Förhöjda IgE-
antikroppsnivåer mot vanliga födoämnen vid fyra och åtta år, födoämnesöverkänslighet och 
födoämnesallergi var också associerade till buksmärta vid 12 år.  
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Vi kunde identifiera 735 mammor som rökte under graviditeten men som slutade innan 
barnet föddes. Trots rökstoppet fanns en signifikant ökad risk för andningsbesvär och astma 
hos barnet när det var fyra till sex år gammalt. Risken ökade också med antalet rökta 
cigaretter under första trimestern av graviditeten i denna grupp av mammor. Vi kunde även 
konstatera att den signifikant ökade risken för andningsbesvär och astma återfanns hos 
förskolebarnen till mammor som rökte under första men inte under tredje trimestern och inte 
heller börjat röka igen efter att barnet fötts. 
Vi kunde inte påvisa några säkra samband mellan mammans rökning under graviditeten eller 
rökning nära spädbarnet under de första månaderna efter födelsen och förekomst av IgE-
antikroppar mot pälsdjur, dammkvalster eller pollen hos barnen när de var tre till fyra eller 
sex till åtta år gamla. Det fanns ett samband mellan rökning nära spädbarnet och IgE-
antikroppar mot pälsdjur vid tre till fyra års ålder, men detta samband kvarstod inte vid sex 
till åtta års ålder. 
Slutsatser 
De faktorer som medför en ökad risk för astmautveckling i barndomen hos barnen med 
astmaliknande andningsbesvär tidigt i livet är en ökad svårighetsgrad av dessa besvär, 
ärftlighet och samtidigt eksem. Dessa resultat är i samklang med liknande studier. 
Det signifikanta sambandet mellan allergirelaterade sjukdomar, allergisk sensibilisering och 
återkommande buksmärta stärker hypotesen om att det kan föreligga ett gemensamt 
immunologiskt ursprung mellan allergi och buksmärta, och att en låggradig inflammation kan 
finnas i tarmen hos barn med allergiska symptom.  
Mammas rökning under graviditeten ökar risken för andningsbesvär och astma hos barnet i 
förskoleåldern även om hon slutat röka under graviditeten. Denna information är viktig att 
delge de kvinnor som planerar att bli gravida, så att de kan motiveras till att sluta röka innan 
graviditeten.  
Inga säkra samband kan påvisas mellan rökning i graviditeten eller nära det nyfödda barnet 
och ökad förekomst av IgE-antikroppar mot pälsdjur, dammkvalster eller pollen i förskole- 
eller tidig skolålder i denna avhandling. 
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